OA18797A - Compositions comprising bacterial strains. - Google Patents
Compositions comprising bacterial strains. Download PDFInfo
- Publication number
- OA18797A OA18797A OA1201800181 OA18797A OA 18797 A OA18797 A OA 18797A OA 1201800181 OA1201800181 OA 1201800181 OA 18797 A OA18797 A OA 18797A
- Authority
- OA
- OAPI
- Prior art keywords
- composition
- compositions
- disease
- treating
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 312
- 230000001580 bacterial Effects 0.000 title claims abstract description 144
- 206010003816 Autoimmune disease Diseases 0.000 claims abstract description 23
- 200000000018 inflammatory disease Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims description 95
- 208000006673 Asthma Diseases 0.000 claims description 72
- 108050003558 Interleukin-17 family Proteins 0.000 claims description 59
- 210000004027 cells Anatomy 0.000 claims description 52
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 claims description 49
- 206010046851 Uveitis Diseases 0.000 claims description 48
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 36
- 241000894007 species Species 0.000 claims description 30
- 201000006417 multiple sclerosis Diseases 0.000 claims description 29
- 210000000936 Intestines Anatomy 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 21
- 206010029379 Neutrophilia Diseases 0.000 claims description 20
- 206010003246 Arthritis Diseases 0.000 claims description 14
- 229920001670 16S ribosomal RNA Polymers 0.000 claims description 12
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 12
- 208000008795 Neuromyelitis Optica Diseases 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 8
- 239000000546 pharmaceutic aid Substances 0.000 claims description 8
- 229920002973 ribosomal RNA Polymers 0.000 claims description 7
- 206010011401 Crohn's disease Diseases 0.000 claims description 6
- 206010023232 Joint swelling Diseases 0.000 claims description 6
- 206010057430 Retinal injury Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 206010003645 Atopy Diseases 0.000 claims description 5
- 208000009137 Behcet Syndrome Diseases 0.000 claims description 5
- 201000008335 Behcet's disease Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 206010039083 Rhinitis Diseases 0.000 claims description 5
- 206010039705 Scleritis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 201000001320 atherosclerosis Diseases 0.000 claims description 5
- 201000004624 dermatitis Diseases 0.000 claims description 5
- 231100000406 dermatitis Toxicity 0.000 claims description 5
- 230000024949 interleukin-17 production Effects 0.000 claims description 5
- 201000001245 periodontitis Diseases 0.000 claims description 5
- 201000004681 psoriasis Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 229960005486 vaccines Drugs 0.000 claims description 5
- 108009000283 Allograft Rejection Proteins 0.000 claims description 4
- 206010009839 Coeliac disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 4
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 4
- 201000006704 ulcerative colitis Diseases 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 210000000068 Th17 Cells Anatomy 0.000 claims 1
- 102100008982 IL17A Human genes 0.000 description 66
- 230000037361 pathway Effects 0.000 description 44
- 230000001404 mediated Effects 0.000 description 39
- 241000089032 Erysipelatoclostridium Species 0.000 description 34
- 241000894006 Bacteria Species 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 28
- 239000003814 drug Substances 0.000 description 24
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 230000028709 inflammatory response Effects 0.000 description 20
- 108020004465 16S Ribosomal RNA Proteins 0.000 description 19
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 18
- 230000001225 therapeutic Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 210000000988 Bone and Bones Anatomy 0.000 description 14
- 210000000349 Chromosomes Anatomy 0.000 description 14
- 230000001684 chronic Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 13
- 230000002207 retinal Effects 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000002068 genetic Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 201000007270 liver cancer Diseases 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 9
- 210000000845 Cartilage Anatomy 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 101710003110 IL17A Proteins 0.000 description 8
- 210000000440 Neutrophils Anatomy 0.000 description 8
- 102100016799 RBP3 Human genes 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 8
- 230000036961 partial Effects 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 210000003979 Eosinophils Anatomy 0.000 description 7
- 241000736262 Microbiota Species 0.000 description 7
- 210000004080 Milk Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000000813 microbial Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 235000020945 retinal Nutrition 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 230000001058 adult Effects 0.000 description 6
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 239000011604 retinal Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 206010007710 Cartilage injury Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 210000003608 Feces Anatomy 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- -1 1L-17A Proteins 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000000987 Immune System Anatomy 0.000 description 4
- 229960001375 Lactose Drugs 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 4
- 229910052767 actinium Inorganic materials 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000002238 attenuated Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 230000002757 inflammatory Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000529 probiotic Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 210000001612 Chondrocytes Anatomy 0.000 description 3
- 208000002691 Choroiditis Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 210000004969 Inflammatory Cells Anatomy 0.000 description 3
- 210000001503 Joints Anatomy 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000003971 Posterior Uveitis Diseases 0.000 description 3
- 206010039580 Scar Diseases 0.000 description 3
- 102100009534 TNF Human genes 0.000 description 3
- 101710040537 TNF Proteins 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 201000009030 carcinoma Diseases 0.000 description 3
- 230000001332 colony forming Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000003045 fructo oligosaccharides Chemical class 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000002519 immonomodulatory Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 150000002482 oligosaccharides Polymers 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000000790 osteoblast Effects 0.000 description 3
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 3
- 230000004256 retinal image Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007169 ycfa-medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- BXTJCSYMGFJEID-XMTADJHZSA-N (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-[3-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- IVRXNBXKWIJUQB-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229950007998 Demcizumab Drugs 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 241000126130 Ganymedes Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101700086956 IFNG Proteins 0.000 description 2
- 102100016020 IFNG Human genes 0.000 description 2
- 102100015970 IL17C Human genes 0.000 description 2
- 102100015975 IL17F Human genes 0.000 description 2
- 101700007032 IL17F Proteins 0.000 description 2
- 102100014204 IL22 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 Inulin Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229950010203 Nimotuzumab Drugs 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- 108091005180 TB-403 Proteins 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 229950008718 Vantictumab Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- 108010029475 demcizumab Proteins 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 108010043585 nimotuzumab Proteins 0.000 description 2
- 108010045555 obinutuzumab Proteins 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000000174 oncolytic Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108010026911 ramucirumab Proteins 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 201000000582 retinoblastoma Diseases 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 210000004215 spores Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3E)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- MUVQOOPKPBEAJZ-VQHVLOKHSA-N (4E)-4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Cl)=C1 MUVQOOPKPBEAJZ-VQHVLOKHSA-N 0.000 description 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 1
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 108010091846 ABT-414 Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 108091002522 AGS-16C3F Proteins 0.000 description 1
- 229960004784 ALLERGENS Drugs 0.000 description 1
- 108010057854 ALT-801 Proteins 0.000 description 1
- 108010057840 ALT-803 Proteins 0.000 description 1
- 108010083275 AV-203 Proteins 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 229940035938 Adcetris Drugs 0.000 description 1
- 229950009084 Adecatumumab Drugs 0.000 description 1
- 108010026410 Ado-Trastuzumab Emtansine Proteins 0.000 description 1
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229960001686 Afatinib Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 229940110282 Alimta Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229950006588 Anetumab ravtansine Drugs 0.000 description 1
- 229940110584 Arzerra Drugs 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010049700 BHQ880 Proteins 0.000 description 1
- 108010072524 BKT140 Proteins 0.000 description 1
- 206010004017 Bacterial disease carrier Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229950007843 Bavituximab Drugs 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229940101815 Blincyto Drugs 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 1
- 229960000455 Brentuximab vedotin Drugs 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 229940088954 Camptosar Drugs 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 229950000771 Carlumab Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229950006647 Cixutumumab Drugs 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 229940034568 Cometriq Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940050303 Cyramza Drugs 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 108010043242 Denosumab Proteins 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229950000006 Ecromeximab Drugs 0.000 description 1
- 229960004137 Elotuzumab Drugs 0.000 description 1
- 229950004647 Emactuzumab Drugs 0.000 description 1
- 229950003048 Enavatuzumab Drugs 0.000 description 1
- 229950004270 Enoblituzumab Drugs 0.000 description 1
- 229950001752 Enoticumab Drugs 0.000 description 1
- 229950010640 Ensituximab Drugs 0.000 description 1
- 229950006370 Epacadostat Drugs 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010042984 FG 3019 Proteins 0.000 description 1
- 241000272190 Falco peregrinus Species 0.000 description 1
- 229950010320 Flanvotumab Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229950000456 Galunisertib Drugs 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 229940054499 Gazyva Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 description 1
- 229940020967 Gemzar Drugs 0.000 description 1
- 229940087158 Gilotrif Drugs 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 229940118951 Halaven Drugs 0.000 description 1
- 229940116364 Hard Fat Drugs 0.000 description 1
- 229940025294 Hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K Hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 102000027098 IL-17 family Human genes 0.000 description 1
- 108091013083 IL-17 family Proteins 0.000 description 1
- 102100015971 IL17B Human genes 0.000 description 1
- 101700044982 IL17B Proteins 0.000 description 1
- 101700034529 IL17C Proteins 0.000 description 1
- 102100015969 IL17D Human genes 0.000 description 1
- 102100014201 IL23R Human genes 0.000 description 1
- 102100014200 IL26 Human genes 0.000 description 1
- 101700054270 IL26 Proteins 0.000 description 1
- 229940111707 IXEMPRA Drugs 0.000 description 1
- 101710002465 IZUMO1R Proteins 0.000 description 1
- 229950005646 Imgatuzumab Drugs 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 229950009034 Indoximod Drugs 0.000 description 1
- 108010027059 Inotuzumab Ozogamicin Proteins 0.000 description 1
- 229950004101 Inotuzumab ozogamicin Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 229950001014 Intetumumab Drugs 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000006617 Islet Cell Carcinoma Diseases 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 229940089787 KADCYLA Drugs 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 229940022039 Keytruda Drugs 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- CBNAAKBWBABMBY-LQCKLLCCSA-N Labetuzumab-SN38 Chemical compound N([C@@H](CCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O CBNAAKBWBABMBY-LQCKLLCCSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 229950002950 Lintuzumab Drugs 0.000 description 1
- 229950011263 Lirilumab Drugs 0.000 description 1
- 229940024740 Lonsurf Drugs 0.000 description 1
- 229950004563 Lucatumumab Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010013585 MDX-1203 Proteins 0.000 description 1
- 108010075841 MEDI3617 Proteins 0.000 description 1
- 229940062713 MITE EXTRACT Drugs 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229950001869 Mapatumumab Drugs 0.000 description 1
- 229950003135 Margetuximab Drugs 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108009000330 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 229950007699 Mogamulizumab Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229950000720 Moxetumomab pasudotox Drugs 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 210000003007 Myelin Sheath Anatomy 0.000 description 1
- VNBRGSXVFBYQNN-UHFFFAOYSA-N N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(N)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 description 1
- 229950002697 Nesvacumab Drugs 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229940080607 Nexavar Drugs 0.000 description 1
- 108010019706 Nivolumab Proteins 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- 229950000846 Onartuzumab Drugs 0.000 description 1
- 241001644482 Onyx Species 0.000 description 1
- 229940098444 Opdivo Drugs 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108010086918 PSMA ADC Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- 229950004260 Parsatuzumab Drugs 0.000 description 1
- 229950010966 Patritumab Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229940039551 Perjeta Drugs 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 229960003733 Phenylephrine Hydrochloride Drugs 0.000 description 1
- 229950010773 Pidilizumab Drugs 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 210000001747 Pupil Anatomy 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 108010077454 RG7356 Proteins 0.000 description 1
- 229940100618 Rectal Suppository Drugs 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 210000001210 Retinal Vessels Anatomy 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 229920002049 Ribosomal DNA Polymers 0.000 description 1
- 229950003238 Rilotumumab Drugs 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- MNGBJGFSOBSOSR-MEWBUHPBSA-N SAR3419 Chemical compound CNC(=O)CCCSSC(C)(C)CCC(=O)N(C)C(C)C(=O)OC([C@@]1(O[C@H]1C1C)C)CC(=O)N(C)C(C(=C(OC)C=2)Cl)=CC=2C\C(C)=C\C=C\C(OC)[C@]2(O)NC(=O)O[C@H]1C2 MNGBJGFSOBSOSR-MEWBUHPBSA-N 0.000 description 1
- 108010028116 SAR650984 Proteins 0.000 description 1
- 101700002422 STAT3 Proteins 0.000 description 1
- 229950000106 Samalizumab Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001275117 Seres Species 0.000 description 1
- 229950008684 Sibrotuzumab Drugs 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 102100003096 TNFRSF18 Human genes 0.000 description 1
- 101710038603 TNFRSF18 Proteins 0.000 description 1
- 229950010265 Tabalumab Drugs 0.000 description 1
- 229940081616 Tafinlar Drugs 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 235000002423 Theobroma angustifolium Nutrition 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 235000002425 Theobroma bicolor Nutrition 0.000 description 1
- 235000002424 Theobroma grandiflorum Nutrition 0.000 description 1
- 235000002323 Theobroma simiarum Nutrition 0.000 description 1
- 210000000779 Thoracic Wall Anatomy 0.000 description 1
- 229950004742 Tigatuzumab Drugs 0.000 description 1
- 210000001578 Tight Junctions Anatomy 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N Tivantinib Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 229950005976 Tivantinib Drugs 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229940032510 Trelstar Drugs 0.000 description 1
- 229950007217 Tremelimumab Drugs 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000007548 Tubulointerstitial nephritis and uveitis Diseases 0.000 description 1
- 206010069034 Tubulointerstitial nephritis and uveitis syndrome Diseases 0.000 description 1
- 229950010095 Ulocuplumab Drugs 0.000 description 1
- 229940022919 Unituxin Drugs 0.000 description 1
- 229950005972 Urelumab Drugs 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 210000001745 Uvea Anatomy 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 229950001067 Varlilumab Drugs 0.000 description 1
- 229940058865 Vectibix Drugs 0.000 description 1
- 229950011257 Veliparib Drugs 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 201000003087 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 229950001212 Volociximab Drugs 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 229940049068 Xalkori Drugs 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- 229940055760 Yervoy Drugs 0.000 description 1
- 229950009002 Zanolimumab Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940052129 Zykadia Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 108091003858 adecatumumab Proteins 0.000 description 1
- 229940089792 ado-trastuzumab emtansine Drugs 0.000 description 1
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000002009 allergen Effects 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 108010003824 anetumab ravtansine Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 108010001114 bavituximab Proteins 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 108090000514 blinatumomab Proteins 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 108091020428 carlumab Proteins 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 108091005269 cixutumumab Proteins 0.000 description 1
- 108010050895 clivatuzumab Proteins 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical group CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 108010020644 dalotuzumab Proteins 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 108010031324 daratumumab Proteins 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 108091003638 dinutuximab Proteins 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108010069578 ecromeximab Proteins 0.000 description 1
- 230000001210 effect on neutrophils Effects 0.000 description 1
- 108010061937 elotuzumab Proteins 0.000 description 1
- 108010002909 emactuzumab Proteins 0.000 description 1
- 108010088118 enavatuzumab Proteins 0.000 description 1
- 108091007634 enoticumab Proteins 0.000 description 1
- 108010060104 ensituximab Proteins 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 1
- 201000000297 erysipelas Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 101710042134 hdac1-a Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000002267 hypothalamic Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 108091003908 imgatuzumab Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002998 immunogenetic Effects 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 108010009550 intetumumab Proteins 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 108010018575 lintuzumab Proteins 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 108010020744 lucatumumab Proteins 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 108010021856 mapatumumab Proteins 0.000 description 1
- 108010090277 margetuximab Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- 239000001964 microbiological growth media Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 108010007997 mogamulizumab Proteins 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 108010033813 necitumumab Proteins 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 108010092946 onartuzumab Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 108010035749 parsatuzumab Proteins 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 108091005397 patritumab Proteins 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 108010026276 pembrolizumab Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010042024 pertuzumab Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 108010051812 pidilizumab Proteins 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 201000005746 pituitary adenoma Diseases 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000003334 potential Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 108010011457 rilotumumab Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 108010043794 sibrotuzumab Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 108010056973 siltuximab Proteins 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 108010072687 sonepcizumab Proteins 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002889 sympathetic Effects 0.000 description 1
- 108010029352 tabalumab Proteins 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002885 thrombogenetic Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 108010092179 tigatuzumab Proteins 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010072993 tremelimumab Proteins 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 108091005340 ulocuplumab Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 108010053952 urelumab Proteins 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000001982 uveitic Effects 0.000 description 1
- 108010071239 varlilumab Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 108010031272 volociximab Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 108010052251 zanolimumab Proteins 0.000 description 1
Abstract
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
Description
COMPOSITIONS COMPRISING BACTERIAL STRAINS
TECHNICAL FIELD
This invention is in the field of compositions comprising bacterial strains isolated from the mammalian digestive tract and the use of such compositions in the treatment of disease.
BACKGROUND TO THE INVENTION
The human intestine is thought to be stérile in utero, but it is exposed to a large variety of maternai and environmental microbes immediately after bîrth. Thereafter, a dynamic period of microbial colonization and succession occurs, which is influenced by factors such as delivery mode, environment, diet and host génotype, ail of which impact upon the composition of the gut microbiota, particularly during early life. Subsequently, the microbiota stabilizes and becoines adult-like [l ]. The human gut microbiota contains more than 500-1000 different phylotypes belonging essentially to two major bacterial divisions, the Bacteroidetes and the Fîrmicutes [2]. The successful symbiotic relationships arising from bacterial colonization of the human gut hâve yielded a wide variety of metabolic, structural, protective and other bénéficiai functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible dietary components are degraded with release of by-products providing an important nutrient source for the host. Similarly, the immunological importance of the gut microbiota is well-recognized and is exemplified in germfree animais which hâve an impaired immune system that is functionally reconstituted following the introduction of commensal bacteria [3-5].
Dramatic changes in microbiota composition hâve been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of Clostridium cluster XlVa bacteria are reduced in IBD patients whilst numbers of E. coli are increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9], Interestingly, this microbial dysbiosis is also associated with imbalances in T effector cell populations.
In récognition of the potential positive effect that certain bacterial strains may hâve on the animal gut, various strains hâve been proposed for use in the treatment of various diseases (see, for example, [10-13]). Also, certain strains, including mostly Lactobacdlus and Bifîdobactenum strains, hâve been proposed for use in treating various inflammatory and autoimmune diseases that are not directly linked to the intestines (see [14] and [15] for reviews). However, the relationship between different diseases and different bacterial strains, and the précisé effects of particular bacterial strains on the gut and at a systemic level and on any particular types of diseases, are poorly characterised.
Seres Health, Inc. (see [16]) spéculâtes that bacteria obtained from faecal samples may be useful for treating immune system disorders but no guidance are provided as to which bacteria would be effective.
Honda et al. (see [17]) describes how a mixture of 20 bacteria of different généra, including species from the Clostridium genus, induce the prolifération and accumulation of Thl7 cells. Honda et al.’s compositions are said to be useful for improving immune functions and preventing or treating înfectious diseases. However, Honda et al. teaches that in order to treat autoimmune and inflammatory disease in an individual, the Thl7-inducing bacteria should be inhibited or kilied, for example, by administering an antibiotic to the patient.
There is a requirement in the art for new methods of treating inflammatory and autoimmune diseases. There is also a requirement for the potential effects of gut bacteria to be characterised so that new thérapies using gut bacteria can be developed.
SUMMARY OF THE INVENTION
The inventors hâve developed new thérapies for treating and preventing inflammatory and autoimmune diseases. In particular, the inventors hâve developed new thérapies for treating and preventing diseases and conditions mediated by IL-17 or the Thl7 pathway. In particular, the inventors hâve identified that bacterial strains from the genus Eiysipelatoclostridiitm can be effective for treating and preventing diseases and conditions mediated by 1L-I7 or the Thl7 pathway. As described in the examples, oral administration of compositions comprising Eiysipelatoclostridiuni ramosum may reduce the severity of the inflammatory response, including the Thl7 inflammatory response, in mouse models of uveitis.
Therefore, in a first embodiment, the invention provides a composition comprising a bacterial strain of the genus Eiysipelaloclostridium, for use in a method of treating or preventing a disease or condition mediated by IL-17 or the ThI7 pathway. The inventors hâve identified that treatment with bacterial strains from this species can provide clinical benefits in mouse models of inflammatory and autoimmune diseases mediated by IL-17 and the Thl7 pathway, may reduce levels of cytokines that are part of the Thl7 pathway, including IL-17, and may alleviate the Thl7 inflammatory response.
In particular embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing a disease or condition selected from the group consisting of: uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psorîatîc arthritis, or juvénile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; celiac disease; asthma, such as allergie asthma or neutrophilie asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopie dermatitis; emphysema; periodontitis; allergie rhinitis; and allograft rejectîon. The effect shown for the bacterial strains from the genus Etysipelatoclostridium on the Thl7 inflammatory response and on diseases mediated by IL-17 and the Thl7 pathway may provide therapeutic benefits for other diseases and conditions mediated by IL17 and the Th 17 pathway, such as those listed above.
In particularly preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing uveitis, such as posterior uveitis. The inventors hâve identified that treatment with Erysipelatoclostridium strains can reduce disease incidence and disease severity in a mouse model of uveitis and can prevent or reduce retinal damage. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum, for use in the treatment of uveitis. Compositions using Erysipelatoclostridium ramosum may be particularly effective for treating uveitis.
In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing asthma, such as neutrophilie asthma or allergie asthma. Treatment with Erysipelatoclostridium strains may reduce recruitment of neutrophils and eosinophils into the lungs, which can help treat or prevent asthma. In certain embodiments, the composition is for use in a method of treating or preventing neutrophilie asthma or éosinophilie asthma. The compositions of the invention may be particularly effective for treating or preventing neutrophilie asthma and éosinophilie asthma. Indeed, in certain embodiments, the composition is for use in a method of reducing a neutrophilie inflammatory response in the treatment or prévention of asthma, or the composition is for use in a method of reducing an éosinophilie inflammatory response in the treatment or prévention of asthma. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum for use in the treatment of asthma, and in particular éosinophilie or allergie asthma. Also, Erysipelatoclostridium ramosum may hâve a particularly pronounced effect on neutrophils in asthma models and treatment with Erysipelatoclostridium ramosum may be particularly effective for treating neutrophilie asthma.
In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing rheumatoid arthritis. Treatment with Erysipelatoclostridium strains may provide clinical benefits in a mouse model of rheumatoid arthritis and reduce joint swelling. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum, for use in the treatment of rheumatoid arthritis. Compositions using Erysipelatoclostridium ramosum may be particularly effective for treating rheumatoid arthritis.
In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing multiple sclerosis. Treatment with Erysipelatoclostridium strains may reduce disease incidence and disease severity in a mouse model of multiple sclerosis. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum, for use in the treatment of multiple sclerosis. Compositions using Erysipelatoclostridium ramosum may be particularly effective for treating multiple sclerosis.
In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for use in a method of treating or preventing cancer, such as breast, lung or liver cancer. Compositions comprising a bacterial strain of the genus Erysipelatoclostridium may reduce tumour growth in mouse models of breast, lung and liver cancer. In certain embodiments, the composition is for use in a method of reducing tumour size or preventing tumour growth in the treatment of cancer. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum, for use in the treatment of cancer.
In certain embodiments, the compositions of the invention are for use in a method of reducing IL-17 production or reducing Thl7 cell différentiation in the treatment or prévention of a disease or condition mediated by IL-17 or the Thl7 pathway. In particular, the compositions of the invention may be used in reducing IL-17 production or reducing Thl7 cell différentiation in the treatment or prévention of asthma, rheumatoid arthritis, multiple sclerosis, uveitis or cancer. Preferably, the invention provides compositions comprising a bacterial strain of the genus Erysipelatoclostridium ramosum, for use in reducing IL-17 production or reducing Thl7 cell différentiation in the treatment or prévention of asthma, rheumatoid arthritis, multiple sclerosis, uveitis or cancer.
In certain embodiments, the composition is for use in a patient with elevated IL-17 levels or Thl7 cells. The effect shown for Erysipelatoclostridium strains on uveitis, which is strongly associated with the Thl7 inflammatory response, means that Erysipelatoclostridium strains may be particularly bénéficiai for such patients.
In preferred embodiments of the invention, the bacterial strain in the composition is of Erysipelatoclostridium ramosum. Closely related strains may also be used, such as bacterial strains that hâve a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the I6s rRNA sequence of a bacterial strain of Erysipelatoclostridium ramosum. Preferably, the bacterial strain has a I6s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:l, 2 or 3, Preferably, the sequence identity is to SEQ ID NO:3. Preferably, the bacterial strain for use in the invention has the 16s rRNA sequence represented by SEQ ID NO:3.
In certain embodiments, the composition of the invention is for oral administration. Oral administration of the strains of the invention can be effective for treating IL-17- or Th 17 pathwaymediated diseases and conditions. Also, oral administration is convenient for patients and practitioners and allows delivery to and / or partial or total colonisation ofthe intestine.
In certain embodiments, the composition of the invention comprises one or more pharmaceutically acceptable excipients or carriers.
In certain embodiments, the composition of the invention comprises a bacterial strain that has been lyophilised. Lyophilisation is an effective and convenient technique for preparing stable compositions that allow delivery of bacteria.
In certain embodiments, the invention provides a food product comprising the composition as described above.
In certain embodiments, the invention provides a vaccine composition comprising the composition as described above.
Additionally, the invention provides a method of treating or preventing a disease or condition mediated by IL-17 or the Thl7 pathway, comprising administering a composition comprising a bacterial strain of the genus Eiysipelatoclostridium.
In developing the above invention, the inventors hâve identified and characterised a bacterial strain that is particularly useful for therapy. The Erysipelatoclostridium ramosum strain of the invention is shown to be effective for treating the diseases described herein, such as uveitis. Therefore, in another aspect, the invention provides a cell of the Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688), or a dérivative thereof. The invention also provides compositions comprising such cells, or biologically pure cultures of such cells. The invention also provides a cell of Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688), or a dérivative thereof, for use in therapy, in particular for the diseases described herein.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1: Mouse model of uveitis - TEFI Scores in the control group. Data are presented as Mean ± SEM.
Figure 2: Mouse model of uveitis - TEFI Scores on Day 28. Data are presented as Mean ± SEM.
DISCLOSURE OFTHE INVENTION
Bacterial strains
The compositions of the invention comprise a bacterial strain of the genus Erysipelatoclostridium. The examples demonstrate that bacteria of this genus are useful for treating or preventing uveitis and diseases and conditions mediated by IL-17 or the Th 17 pathway. The preferred bacterial strains are of the species Erysipelatoclostridium ramosum.
The invention provides an Erysipelatoclostridium, for example, an Erysipelatoclostridium ramosum for use în therapy, for example, for use in treating or preventing an inflammatory and/or autoimmune disease. Similarly, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium, for example, an Erysipelatoclostridium ramosum, for use in therapy, for example, for use in treating or preventing an inflammatory and/or autoimmune disease. In certain embodiments, the compositions of the invention comprise Erysipelatoclostridium, for example, an Erysipelatoclostridium ramosum. and do not contain any other bacterial genus. In certain embodiments, the compositions of the invention comprise a single species of Erysipelatoclostridium, for example, an Erysipelatoclostridium ramosum, and do not contain any other bacterial species. In certain embodiments, the compositions of the invention comprise a single strain of Erysipelatoclostridium, for example, of Erysipelatoclostridium ramosum, and do not contain any other bacterial strains or species.
Examples of Erysipelatoclostridium species for use in the invention include Erysipelatoclostridium ramosum, (Clostridium) cocleatum, (C.) saccharogumia, (C.) spiroforme, and (C.) innocuum (recently reclassified in [18]). Erysipelatoclostridium are gram-positively staining, non-motile, obligately anaérobie straight or helically curved rods of 0.3-1.0 pmx2- 4 pm. Spore formation is rare or absent. Accordingly, in some embodiments of the invention, the Erysipelatoclostridium bacterial strain is not in sporulated form or if any spores are présent they are présent in a de minimis amount. The G+C content of the genomic DNA is 27-33 mol%. They ferment glucose, fructose and sucrose [18]. The type strain of Erysipelatoclostridium ramosum is ATCC 25582 = DSM 1402. The GenBank accession number for the 16S rRNA gene sequence of Erysipelatoclostridium ramosum strain DSM 1402 is X73440 (disclosed herein as SEQ ID NO:1). Exemplary Erysipelatoclostridium ramosum strains are described in [18], Another strain for use in the invention is Erysipelatoclostridium ramosum strain JCM 1298. The GenBank accession number for the 16S rRNA gene sequence of Erysipelatoclostridium ramosum strain JCM 1298 is NR_113243.1 (disclosed herein as SEQ ID NO:2).
The Erysipelatoclostridium ramosum bacterium tested in the Examples is referred to herein as strain MRX027. A 16S rRNA sequence for the MRX027 strain that was tested is provided în SEQ ID NO:3. Strain MRX027 was deposited with the international depositary authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Scotland) on 15th November 2016 and was assigned accession number NCIMB 42688. The tenus “MRX027” and “MRx0027” are used interchangeably herein.
Bacterial strains closely related to the strain tested in the examples are also expected to be effective for treating or preventing uveitis and diseases and conditions mediated by IL-17 or the Th 17 pathway. In certain embodiments, the bacterial strain for use in the invention has a I6s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identicai to the I6s rRNA sequence of a bacterial strain of Erysipelatoclostridium ramosum. Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identicai to SEQ ID NO:l, 2 or 3. Preferably, the sequence identity is to SEQ ID NO:3. Preferably, the bacterial strain for use in the invention has the I6s rRNA sequence represented by SEQ ID NO:3.
Bacterial strains that are biotypes of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 and JCM 1298 are also expected to be effective for treating or preventing uveitis and diseases and conditions mediated by IL-17 or the Th 17 pathway. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.
Strains that are biotypes of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 and that are suitable for use in the invention may be identified by sequencing other nucléotide sequences for strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298. For example, substantially the whole genome may be sequenced and a biotype strain for use in the invention may hâve at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity across at least 80% of its whole genome (e.g. across at least 85%, 90%, 95% or 99%, or across its whole genome). For example, in some embodiments, a biotype strain has at least 98% sequence identity across at least 98% of its genome or at least 99% sequence identity across 99% of its genome. Other suitable sequences for use in identifying biotype strains may include hsp60 or répétitive sequences such as BOX, ERIC, (GTG),, or REP or [19], Biotype strains may hâve sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298. In some embodiments, a biotype strain has a sequence with at least 95%, 96%, 97%, 98%, 99%, 99,5% or 99.9% sequence identity to the corresponding sequence of strain MRX027 deposited as NCIMB 42688 and comprises a 16S rRNA sequence that is at least 99% identicai (e.g. at least 99.5% or at least 99.9% identicai) to SEQ ID NO:3. In some embodiments, a biotype strain has a sequence with at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of strain MRX027 deposited as NCIMB 42688 and has the 16S rRNA sequence of SEQ ID NO:3.
Alternatively, strains that are biotypes of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 and that are suitable for use în the invention may be identified by using strain strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 and restriction fragment analysis and/or PCR analysis, for example by using fluorescent amplified fragment length polymorphism (FAFLP) and répétitive DNA element (rep)-PCR fingerprinting, or protein profiling, or partial 16S or 23s rDNA sequencing. In preferred embodiments, such techniques may be used to identity other Erysipelatoclostridium ramosum strains.
In certain embodiments, strains that are biotypes of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 and that are suitable for use in the invention are strains that provide the same pattern as strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 when analysed by amplified ribosomal DNA restriction analysis (ARDRA), for example when using Sau3AI restriction enzyme (for exemplary methods and guidance see, for example,[20]). Alternatively, biotype strains are identified as strains that hâve the same carbohydrate fermentation pattems as strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM I298.
Other Erysipelatoclostridium ramosuni strains that are useful in the compositions and methods of the invention, such as biotypes of strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM I298, may be identified using any appropriate method or strategy, including the assays described in the examples. For instance, strains for use in the invention may be identified by culturing in anaérobie YCFA and/or administering the bacteria to the type II collagen-induced arthritis mouse model and then assessing cytokine levels. In particular, bacterial strains that hâve similar growth pattems, metabolic type and/or surface antigens to strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298 may be useful in the invention. A useful strain will hâve comparable immune modulatory activity to strains MRX027 (in particular MRX027 deposited as NCIMB 42688), ATCC 25582 or JCM 1298. In particular, a biotype strain will elicit comparable effects on the uveitis disease models to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples.
A particularly preferred strain of the invention is strain MRX027 strain (in particular MRX027 deposited as NCIMB 42688). This îs the exemplary strain tested in the examples and shown to be effective for treating disease. Therefore, the invention provides a cell, such as an isolated cell, of Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688), or a dérivative thereof. The invention also provides a composition comprising a cell of Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688), or a dérivative thereof. The invention also provides a bîologically pure culture of Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688). The invention also provides a cell of Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688), or a dérivative thereof, for use in therapy, in particular for the diseases described herein. A dérivative of Erysipelatoclostridium ramosum strain
MRX027 (in particular MRX027 deposited as NCIMB 42688) may be a daughter strain (progeny) or a strain cultured (subcloned) from the original.
A dérivative of a strain of the invention may be modified, for example at the genetic level, without ablating the biological activity. In particular, a dérivative strain of the invention is therapeutic ail y active. A dérivative strain will hâve comparable immune modulatory activity to the Erysipelatoclostridium ramosum strain MRX027 (in particular MRX027 deposited as NCIMB 42688). In particular, a dérivative strain will elicit comparable effects on the uveitis disease models to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples. A dérivative of strain MRX027 (in particular MRX027 deposited as NCIMB 42688) will generally be a biotype of strain MRX027 (in particular MRX027 deposited as NCIMB 42688).
Référencés to cells of Erysipelatoclostridium ramosum strain MRX027 encompass any cells that hâve the same safety and therapeutic efficacy characteristics as strain MRX027, and such cells are encompassed by the invention. Reference to MRX027 deposited as NCIMB 42688 refers to the deposited MRX027 strain only.
The genome sequence of Erysipelatoclostridium ramosum strain DSM 1402 is disclosed herein as SEQ ID NO:4. SEQ ID NO:4 is disclosed and published în WO 2017/089794. This sequence is a genomic scaffbld obtained using whole genome shotgun sequencing and is also available using GenBank accession number NZ DS499659.1. In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:4. In some embodiments, the bacterial strain for use in the invention has a chromosome with at least 90% sequence identity (e.g. at least 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to SEQ ID NO:4 across at least 30% (e.g. across at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO:4. For example, the bacterial strain for use in the invention may hâve a chromosome with at least 95% sequence identity to SEQ ID NO:4 across 35% of SEQ ID NO:4, or at least 95% sequence identity to SEQ ID NO:4 across 45% of SEQ ID NO:4, or at least 90% sequence identity to SEQ ID NO:4 across 70% of SEQ ID NO:4, or at least 90% sequence identity to SEQ ID NO:4 across 80% of SEQ ID NO:4, or at least 90% sequence identity to SEQ ID NO:4 across 90% of SEQ ID NO:4, or at least 90% sequence identity to SEQ ID NO:4 across 100% of SEQ ID NO:4, or at least 95% sequence identity to SEQ ID NO:4 across 70% of SEQ ID NO:4, or at least 95% sequence identity to SEQ ID NO:4 across 80% of SEQ ID NO:4, or at least 95% sequence identity to SEQ ID NO:4 across 90% of SEQ ID NO:4, or at least 95% sequence identity to SEQ ID NO:4 across 100% of SEQ ID NO:4, or at least 98% sequence identity to SEQ ID NO:4 across 70% of SEQ ID NO:4, or at least 98% sequence identity to SEQ ID NO:4 across 80% of SEQ ID NO:4, or at least 98% sequence identity to SEQ ID NO:4 across 90% of SEQ ID NO:4, or at
ΙΟ least 98% identity across 95% of SEQ ID NO:4, or at least 98% sequence identity to SEQ ID NO:4 across 100% of SEQ ID NO:4, or at least 99.5% sequence identity to SEQ ID NO:4 across 90% of SEQ ID NO:4, or at least 99.5% identity across 95% of SEQ ID NO:4, or at least 99.5% identity across 98% of SEQ ID NO:4, or at least 99.5% sequence identity to SEQ ID NO:4 across 100% of SEQ ID NO:4.
In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:4 in the région flanking the 16S rRNA sequence. In some embodiments, the bacterial strain for use in the invention has a chromosome with at least 95% (e.g. at least 96%, 97%, 98%, 99%, 99.5% or 100%) sequence identity to the 0.5kb sequence directly upstream and/or downstream of the 16S rRNA sequence in SEQ ID NO:4. In some embodiments, the bacterial strain for use in the invention has a chromosome with at least 95% (e.g. at least 96%, 97%, 98%, 99%, 99.5% or 100%) sequence identity to the Ikb sequence directly upstream and/or downstream of the 16S rRNA sequence in SEQ ID NO:4. In some embodiments, the bacterial strain for use in the invention has a chromosome with at least 95% (e.g. at least 96%, 97%, 98%, 99%, 99.5% or 100%) sequence identity to the 1,5kb sequence directly upstream and/or downstream of the 16S rRNA sequence in SEQ ID NO:4. In some embodiments, the bacterial strain for use in the invention has a chromosome with at least 95% (e.g. at least 96%, 97%, 98%, 99%, 99.5% or 100%) sequence identity to the 2kb sequence directly upstream and/or downstream of the 16S rRNA sequence in SEQ IDNO:4.
In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:4, for example as described above, and a 16S rRNA sequence with sequence identity to any of SEQ ID NO: 1,2 or 3, for example as described above, preferably with a 16s rRNA sequence that is at least 99% identical to SEQ ID NO: 3, more preferably which comprises the 16S rRNA sequence of SEQ ID NO:3.
In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:4, for example as described above, and is effective for treating or preventing diseases and conditions mediated by IL-17 or the Th 17 pathway.
In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:4, for exampie as described above, and a 16S rRNA sequence with sequence identity to any of SEQ ID NOs; 1, 2 or 3, for example as described above, and is effective for treating or preventing diseases and conditions mediated by IL-17 or the Th 17 pathway.
In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 99%, 99.5% or 99.9% identical to the 16s rRNA sequence represented by SEQ ID NO: 3 (for example, which comprises the 16S rRNA sequence of SEQ ID NO:3) and a chromosome with at
U least 95% sequence identity to SEQ ID NO:4 across at least 40% of SEQ ID NO:4, and which is effective for treating or preventing diseases and conditions mediated by IL-l 7 or the Thl 7 pathway.
In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 99%, 99.5% or 99.9% identical to the 16s rRNA sequence represented by SEQ ID NO: 3 (for example, which comprises the 16S rRNA sequence of SEQ ID NO:3) and a chromosome with at least 95% sequence identity to SEQ ID NO:4 across at least 90% of SEQ ID NO:4, and which is effective for treating or preventing diseases and conditions mediated by IL-17 or the Th 17 pathway.
In certain embodiments, the bacterial strain for use in the invention is a Erysipelatoclostridium raniosum and has a 16s rRNA sequence that is at least 99%, 99.5% or 99.9% identical to the 16s rRNA sequence represented by SEQ ID NO: 3 (for example, which comprises the 16S rRNA sequence of SEQ ID NO:3) and a chromosome with at least 98% sequence identity (e.g. at least 99% or at least 99.5% sequence identity) to SEQ ID NO:4 across at least 98% (e.g. across at least 99% or at least 99.5%) of SEQ ID NO:4, and which is effective for treating or preventing diseases and conditions mediated by IL-17 or the Thl 7 pathway.
In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonising the intestine.
Therapeutic uses
As demonstrated in the examples, the bacterial compositions of the invention are effective for reducing the Th 17 inflammatory response. In particular, treatment with compositions of the invention achieves clinical improvements in animal models of conditions mediated by IL-17 and the Th 17 pathway and may achieve a réduction in 1L-17A levels and other Thl7 pathway cytokines. Therefore, the compositions of the invention may be useful for treating or preventing inflammatory and autoimmune diseases, and in particular diseases or conditions mediated by IL-17. In particular, the compositions of the invention may be useful for reducing or preventing élévation of the IL-17 inflammatory response.
Th 17 cells are a subset ofT helper cells that produce, for example, IL-17A, IL17-F, 1L-21 and IL-22. Thl7 cell différentiation and 1L-17 expression may be driven by IL-23. These cytokines and others form important parts of the Th 17 pathway, which is a well-established inflammatory signalling pathway that contributes to and underlies a number of inflammatory and autoimmune diseases (as described in, for example, [21-26]). Diseases wherein the Th 17 pathway is activated are Th 17 pathway-mediated diseases. Th 17 pathway-mediated diseases can be ameliorated or alleviated by repressing the Th 17 pathway, which may be through a réduction in the différentiation of Th 17 cells or a réduction in their activity or a réduction in the level of Th 17 pathway cytokines. Diseases mediated by the Th 17 pathway may be characterised by increased levels of cytokines produced by
Thl7 cells, such as IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-9 (reviewed in [27]). Diseases mediated by the Thl7 pathway may be characterised by increased expression of Th-17-related genes, such as Stat3 or IL-23R. Diseases mediated by the Thl7 pathway may be associated with increased levels of Thl 7 cells.
IL-17 is a pro-inflammatory cytokine that contributes to the pathogenesis of several inflammatory and autoimmune diseases and conditions. IL-l 7 as used herein may refer to any member of the IL-17 family, including 1L-17A, IL-17B, IL-17C, IL-17D, 1L-17E, and IL-17F. IL-l7-mediated diseases and conditions are characterised by high expression of IL-17 and/or the accumulation or presence of IL-l7-positive cells in a tissue affected by the disease or condition. Similarly, IL-l7-mediated diseases and conditions are diseases and conditions that are exacerbated by high IL-17 levels or an increase în IL-17 levels, and that are alleviated by low IL-17 levels or a réduction in IL-17 levels. The IL-17 inflammatory response may be local or systemic.
Examples of diseases and conditions that may be mediated by IL-17 or the Thl7 pathway include uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoîd arthritis, osteoarthritis, psoriatic arthritis, or juvénile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; celiac disease; asthma, such as allergie asthma or neutrophilie asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopie dermatitis; emphysema; periodontitis; allergie rhinitis; and allograft rejection. In preferred embodiments, the compositions of the invention are used for treating or preventing one or more of these conditions or diseases. In further preferred embodiments, these conditions or diseases are mediated by IL-17 or the Thl 7 pathway.
In some embodiments, the pathogenesis of the disease or condition affects the intestine. In some embodiments, the pathogenesis of the disease or condition does not affect the intestine. In some embodiments, the pathogenesis of the disease or condition is not localised at the intestine. In some embodiments, the treating or preventing occurs at a site other than at the intestine. In some embodiments, the treating or preventing occurs at the intestine and also at a site other than at the intestine. In certain embodiments, the disease or condition is systemic.
In certain embodiments, the compositions of the invention are for use in a method of reducing IL-17 production or reducing Thl7 cell différentiation în the treatment or prévention of a disease or condition mediated by IL-17 or the Thl7 pathway. In certain embodiments, the compositions of the invention are for use in treating or preventing an inflammatory or autoimmune disease, wherein said treatment or prévention is achîeved by reducing or preventing élévation of the Thl 7 inflammatory response. In certain embodiments. the compositions of the invention are for use in treating a patient with an inflammatory or autoimmune disease, wherein the patient has elevated IL-17 levels or elevated Thl7 cells or is exhibiting a Thl7 inflammatory response. In certain embodiments, the patient may hâve been diagnosed with a chronic inflammatory or autoimmune disease or condition, or the composition of the invention may be for use in preventing an inflammatory or autoimmune disease or condition developing into a chronic inflammatory or autoimmune disease or condition. In certain embodiments, the disease or condition may not be responsive to treatment with TNF-a inhibitors. These uses of the invention may be applied to any of the spécifie disease or conditions listed in the preceding paragraph.
IL-17 and the Thl7 pathway are often associated with chronic inflammatory and autoimmune diseases, so the compositions of the invention may be particularly useful for treating or preventing chronic diseases or conditions as listed above. In certain embodiments, the compositions are for use in patients with chronic disease. In certain embodiments, the compositions are for use in preventing the development of chronic disease.
The compositions ofthe invention may be useful for treating diseases and conditions mediated by IL17 or the Th 17 pathway and for addressing the Th 17 inflammatory response, so the compositions of the invention may be particularly useful for treating or preventing chronic disease, treating or preventing disease in patients that hâve not responded to other thérapies (such as treatment with TNF-α inhibitors), and/or treating or preventing the tissue damage and symptoms associated with IL17 and Th 17 cells. For example, IL-17 is known to activate matrix destruction in cartilage and bone tissue and IL-17 has an inhibitory effect on matrix production in chondrocytes and osteoblasts, so the compositions of the invention may be useful for treating or preventing bone érosion or cartilage damage.
In certain embodiments, treatment with compositions of the invention provides a réduction or prevents an élévation in IL-17 levels, in particular IL-17A levels. In certain embodiments, treatment with compositions of the invention provides a réduction or prevents an élévation in TNFa, IFN-γ or IL-6 levels. Such réduction or prévention of elevated levels of these cytokines may be useful for treating or preventing inflammatory and autoimmune diseases and conditions, in particular those mediated by IL-17 or the Thl 7 pathway.
Uveitis
In preferred embodiments, the compositions of the invention are for use in treating or preventing uveitis. The examples demonstrate that the compositions of the invention achieve a réduction in disease incidence and disease severity in an animal model of uveitis and so they may be useful in the treatment or prévention of uveitis. Uveitis is inflammation of the uvea and can resuit in retinal tissue destruction. It can présent in different anatomical forms (anterior, intermediate, posterior or diffuse) and resuit from different, but related, causes, including systemic autoimmune disorders. IL-17 and the Thl7 pathway are centrally involved in uveitis, so the efficacy of the compositions of the invention for treating uveitis indicates that the compositions of the invention may be particularly effective for treating and preventing diseases and conditions mediated by IL-17 or the Thl7 pathway. Référencés [28-35] describe elevated sérum levels of interleukin-l 7A in uveitis patients, spécifie association of IL17A genetic variants with panuveitis, the rôle of Thl7-associated cytokines in the pathogenesis of experimental autoimmune uveitis, the imbalance between Thl7 Cells and regulatory T Cells during monophasic experimental autoimmune uveitis, the up-regulation of 1L-17A in patients with uveitis and active Adamantiades-Behçet and Vogt-Koyanagi-Harada (VKH) diseases, the treatment of non-infectious uveitis with seeukinumab (anti-IL-l7A antibody), and Thl7 in uveitic eyes.
In certain embodiments, the uveitis is posterior uveitis. Posterior uveitis présents primarily with inflammation of the retina and choroid and the examples demonstrate that the compositions of the invention are effective for reducing retinal inflammation and damage.
In certain embodiments, treatment with the compositions of the invention results in a réduction in retinal damage. In certain embodiments, the compositions of the invention are for use in reducing or preventing retinal damage in the treatment of uveitis. In certain embodiments, the compositions are for use in treating patients with severe uveitis that are at risk of retinal damage. In certain embodiments, treatment with the compositions of the invention results in a réduction in optic dise inflammation. In certain embodiments, the compositions of the invention are for use în reducing or preventing optic dise inflammation. In certain embodiments, treatment with the compositions of the invention results in a réduction in retinal tissue infiltration by inflammatory cells. In certain embodiments, the compositions of the invention are for use in reducing retinal tissue infiltration by inflammatory cells. In certain embodiments, treatment with the compositions of the invention results in vision being maintained or improved. In certain embodiments, the compositions of the invention are for use in maintaining or improving vision.
In certain embodiments, the compositions are for use in treating or preventing uveitis associated with a non-infectious or autoimmune disease, such as Behçet disease, Crohn's disease, Fuchs hétérochromie iridocyclitis, granulomatosis with polyangiitis, HLA-B27 related uveitis, juvénile idiopathic arthritîs, sarcoidosis, spondyloarthritis, sympathetic ophthalmîa, tubulointerstitial nephritis and uveitis syndrome or Vogt-Koyanagi-Harada syndrome. IL-17A has been shown to be involved in, for example, Behçet and Vogt-Koyanagi-Harada diseases.
Treatment or prévention of uveitis may refer to, for example, an alleviation of the severity of symptoms or a prévention of relapse.
Cancer (n preferred embodiments, the compositions of the invention are for use in treating or preventing cancer. IL-I7 and the Thl7 pathway hâve central rôles in cancer development and progression, and so the compositions of the invention may be useful for treating or preventing cancer.
Although the rôles of IL-l7 and Thl7 cells in cancer are not fully understood, numerous pro-tumour effects of IL-l7 and Thl7 cells are known. For example, Thl7 cells and IL-l7 can promote angiogenesis, increase prolifération and survival of tumor cells and activate tumour-promoting transcription factors [36-38],
In certain embodiments, treatment with the compositions of the invention results in a réduction in tumour size or a réduction in tumour growth. In certain embodiments, the compositions of the invention are for use in reducing tumour size or reducing tumour growth. The compositions of the invention may be effective for reducing tumour size or growth. In certain embodiments, the compositions of the invention are for use in patients with solid tumeurs. In certain embodiments, the compositions of the invention are for use in reducing or preventing angiogenesis in the treatment of cancer. IL-l7 and Thl7 cells hâve central rôles in angiogenesis. In certain embodiments, the compositions of the invention are for use in preventing metastasis.
In certain embodiments, the compositions of the invention are for use in treating or preventing breast cancer. The compositions ofthe invention may be effective for treating breast cancer, and IL-l7 and Thl7 cells hâve important rôles in breast cancer [39], In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments the cancer is mammary carcinoma. In preferred embodiments the cancer is stage IV breast cancer.
In certain embodiments, the compositions of the invention are for use in treating or preventing lung cancer. The compositions of the invention may be effective for treating lung cancer, and IL-l7 and Thl 7 cells hâve important rôles in lung cancer [40]. In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of lung cancer. In preferred embodiments the cancer is lung carcinoma.
In certain embodiments, the compositions of the invention are for use in treating or preventing liver cancer. The compositions of the invention may be effective for treating liver cancer, and IL-l7 and Thl 7 cells hâve important rôles in liver cancer [41]. In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of liver cancer. In preferred embodiments the cancer is hepatoma (hepatocellular carcinoma).
I6
In certain embodiments, the compositions of the invention are for use in treating or preventing carcinoma. The compositions of the invention may be particularly effective for treating carcinoma. In certain embodiments, the compositions of the invention are for use in treating or preventing nonimmunogenic cancer. The compositions of the invention may be effective for treating nonimmunogenic cancers.
In further embodiments, the compositions of the invention are for use in treating or preventing acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma. basal-cell carcinoma, bile duct cancer, bladder cancer, bone tumor, osteosarcoma/malignant fibrous histiocytoma, brainstem glioma, brain tumor, cerebellar astrocytoma, cérébral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cervical cancer, chronic lymphocytic leukemia. chronic myelogenous leukemia, chronic myeloproliférative disorders, colon cancer, cutaneous T-cell lymphoma, endométrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, glioma, childhood visual palhway and hypothalamic, Hodgkin lymphoma, melanoma, islet cell carcinoma, Kaposi sarcoma, rénal cell cancer, laryngeal cancer, leukaemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasia, prostate cancer, rénal cell carcinoma, retinoblastoma, sarcoma, testicular cancer, thyroid cancer, or uterine cancer.
The compositions of the invention may be particularly effective when used in combination with further therapeutic agents. The immune-modulatory effects of the compositions of the invention may be effective when combined with more direct anti-cancer agents. Therefore, in certain embodiments, the invention provides a composition comprising a bacterial strain of the genus Erysipelatoclostridium and an anticancer agent. In preferred embodiments the anticancer agent is an immune checkpoînt inhibitor, a targeted antibody immunotherapy, a CAR.-T cell therapy, an oncolytic virus, or a cytostatic drug. ïn preferred embodiments, the composition comprises an anticancer agent selected from the group consisting of: Yervoy (ipilimumab, BMS); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/Medlmmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/Medlmmune); CT-Oll (pidilizumab, CureTech); BMS986015 (lirilumab, BMS); MEDI0680 (AZ/Medlmmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/Medlmmune); BMS-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prima Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetîcs);
INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (NewLink Genetics); antîVISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women's University, Korea); Vemurafenib (Piexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-1131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); ABT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab estafenatox (Active Biotech); AFM 13 (Affimed); AFMI1 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT836 (Altor Bioscience); ALT-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/Medlmmune); BAY2010112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/Medlmmune); MEDI3617 (AZ/Medlmmune); MEDI6383 (AZ/Medlmmune); MEDI551 (AZ/Medlmmune); Moxetumomab pasudotox (AZ/Medlmmune); MEDI565 (AZ/Medlmmune); MEDI0639 (AZ/Medlmmune); MEDI0680 (AZ/Medlmmune); MEDI562 (AZ/Medlmmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); Bl-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-OlOt (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U31565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly);
I8
LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY30122H (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TRl (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); 1MAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK.); mapatumumab (GSK); 1MGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumabdox (Immunomedics); IMMU-H5 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); 1PH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DH7E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); Xmab5574 (Morphosys); BPC-IC (ensituximab, Précision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880 (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncoined/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIVIA (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganituinab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab25l2 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); MAGE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); CAR-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunwaybio); DNX-2401 (DNAtrix); VCN-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); ProstAtak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold
Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONCl (Genelux); T-VEC (Amgen); G207 (Medigene); HFIO (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienXOlO (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-OOl (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eîsai Pharma), Veliparib (Abbvie), AZD929I (AZ), Alectinib (Chugaî), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GVlOOl (Kael-GemVax), Tivantinib (ArQule); Cytoxan (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); and TS-l (Taiho Pharmaceuticals).
In some embodiments, the one or more Erysipelatoclostridium bacterial strains is/are the only therapeutically active agent(s) in a composition of the invention. In some embodiments, the bacterial strain(s) in the composition is/are the only therapeutically active agent(s) in a composition of the invention.
Asthma
In preferred embodiments, the compositions of the invention are for use in treating or preventing asthma. The compositions of the invention may achieve a réduction in the recruîtment of neutrophils and/or eosinophils into the airways following sensitisation and challenge with house dust mite extract and so they may be useful in the treatment or prévention of asthma. Asthma is a chronic disease characterised by inflammation and restriction of the airways. The inflammation in asthma may be mediated by IL-17 and/or Thl7 cells, and so the compositions of the invention may be particularly effective for preventing or treating asthma. The inflammation in asthma may be mediated by eosinophils and/or neutrophils.
In certain embodiments, the asthma is éosinophilie or allergie asthma. Eosinophilie and allergie asthma are characterised by increased numbers of eosinophils in peripheral blood and in airway sécrétions and is associated pathologically with thickening of the basement membrane zone and pharmacologically by corticosteroid responsiveness [42]. Compositions that reduce or inhibit eosinophil recruîtment or activation may be useful for treating or preventing éosinophilie and allergie asthma.
In additional embodiments, the compositions of the invention are for use in treating or preventing neutrophilie asthma (or non-eosinophilic asthma). High neutrophil numbers are associated with severe asthma that may be insensitive to corticosteroid treatment. Compositions that reduce or inhibit neutrophil recruitment or activation may be useful for treating or preventing neutrophilie asthma.
Eosinophilie and neutrophilie asthma are not mutually exclusive conditions and treatments that help address either the eosinophîl and neutrophil responses may be useful for treating asthma in general.
Increased IL-17 levels and activation of the Thl 7 pathway are associated with severe asthma, so the compositions of the invention may be useful for preventing the development of severe asthma or for treating severe asthma.
In certain embodiments, the compositions of the invention are for use in methods reducing an éosinophilie inflammatory response in the treatment or prévention of asthma, or for use in methods of reducing a neutrophilie inflammatory response in the treatment or prévention of asthma. As noted above, high levels of eosinophils in asthma is associated pathologically with thickening of the basement membrane zone, so reducing éosinophilie inflammatory response in the treatment or prévention of asthma may be able to specifically address this feature of the disease. Also, elevated neutrophils, either in combination with elevated eosinophils or in their absence, is associated with severe asthma and chronic airway narrowing. Therefore, reducing the neutrophilie inflammatory response may be particularly usefol for addressing severe asthma.
In certain embodiments, the compositions reduce perîbronchiolar infiltration in allergie asthma, or are for use in reducing perîbronchiolar infiltration in the treatment of allergie asthma. In certain embodiments, the compositions reduce perîbronchiolar and/or perivascular infiltration in neutrophilie asthma, or are for use in reducing perîbronchiolar and/or perivascular infiltration in the treatment of allergie neutrophilie asthma.
In certain embodiments, treatment with compositions of the invention provides a réduction or prevents an élévation in TNFa levels.
In certain embodiments, the compositions of the invention are for use in a method of treating asthma that results in a réduction of the éosinophilie and/or neutrophilie inflammatory response. In certain embodiments, the patient to be treated has, or has previously been identified as having, elevated neutrophil or eosinophîl levels, for example as identified through blood sampling or sputum analysis.
The compositions of the invention may be useful for preventing the development of asthma in a newbom when administered to the new-bom, or to a prégnant woman. The compositions may be useful for preventing the development of asthma in children. The compositions of the invention may be useful for treating or preventing adult-onset asthma. The compositions of the invention may be useful for managing or alleviating asthma. The compositions of the invention may be particularly useful for reducing symptoms associated with asthma that is aggravated by allergens, such as house dust mites.
Treatment or prévention of asthma may refer to, for example, an alleviation of the severity of symptoms or a réduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.
Arthritis
In preferred embodiments, the compositions of the invention are for use in treating or preventing rheumatoid arthritis (RA). The compositions of the invention may achieve a réduction in the clinical signs of RA in a mouse model, reduce cartilage and bone damage, and reduce the IL-17 inflammatory response, and so they may be useful in the treatment or prévention of RA. RA is a systemic inflammatory disorder that primarily affects joints. RA is associated with an inflammatory response that results in swelling of joints, synovial hyperplasia, and destruction of cartilage and bone. IL-17 and Thl 7 cells may hâve a key rôle in RA, for example because IL-17 inhibits matrix production in chondrocytes and osteoblasts and activâtes the production and fonction of matrix metalloproteinases and because RA disease activity is correlated to IL-17 levels and Th-I7 cell numbers [43,44], so the compositions of the invention may be particularly effective for preventing or treating RA.
In certain embodiments, the compositions of the invention are for use in lowering IL-17 levels or preventing élévation of IL-17 levels in the treatment or prévention of RA. In certain embodiments, treatment with compositions of the invention provides a réduction or prevents an élévation in IL-17 levels, in particular 1L-I7A levels. In certain embodiments, treatment with compositions of the invention provides a réduction or prevents an élévation in IFN-γ or IL-6 levels.
In certain embodiments, treatment with the compositions of the invention results in a réduction in the swelling of joints. In certain embodiments, the compositions of the invention are for use in patients with swollen joints or patients identified as at risk of having swollen joints. In certain embodiments, the compositions of the invention are for use in a method of reducing joint swelling in RA.
In certain embodiments, treatment with the compositions of the invention results in a réduction in cartilage damage or bone damage. In certain embodiments, the compositions of the invention are for use in reducing or preventing cartilage or bone damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patient with severe RA that are at risk of cartilage or bone damage.
Increased IL-17 levels and Thl 7 cell numbers are associated with cartilage and bone destruction in RA [43,44]. IL-17 is known to activate matrix destruction in cartilage and bone tissue and IL-17 has an inhibitory effect on matrix production in chondrocytes and osteoblasts. Therefore, in certain embodiments, the compositions of the invention are for use in preventing bone érosion or cartilage damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patients that exhibit bone érosion or cartilage damage or patients identified as at risk of bone érosion or cartilage damage.
TNF-α is also associated with RA. but TNF-α is not involved in the pathogenesis of the later stages of the disease. In contrast, IL-17 has a rôle throughout ail stages of chronic disease [45]. Therefore, in certain embodiments the compositions of the invention are for use in treating chronic RA or latestage RA, such as disease that includes joint destruction and loss of cartilage. In certain embodiments, the compositions of the invention are for treating patients that hâve previously received anti-TNF-α therapy. In certain embodiments, the patients to be treated do not respond or no longer respond to anti-TNF-α therapy.
The compositions of the invention may be useful for modulating a patient’s immune system, so in certain embodiments the compositions of the invention are for use in preventing RA in a patient that has been identified as at risk of RA, or that has been diagnosed with early-stage RA. The compositions of the invention may be useful for preventing the development of RA.
The compositions of the invention may be useful for managing or alleviating RA. The compositions of the invention may be particularly useful for reducing symptoms associated with joint swelling or bone destruction. Treatment or prévention of RA may refer to, for example, an alleviation of the severity of symptoms or a réduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.
Multiple sclerosis
In preferred embodiments, the compositions of the invention are for use in treating or preventing multiple sclerosis. The compositions of the invention may achieve a réduction in the disease incidence and disease severity in a mouse model of multiple sclerosis (the EAE model), and so they may be useful in the treatment or prévention of multiple sclerosis. Multiple sclerosis is an inflammatory disorder associated with damage to the myelin sheaths of neurons, particularly in the brain and spinal column. Multiple sclerosis is a chronic disease, which is progressively incapacitating and which evolves in épisodes. IL-17 and Thl7 cells may hâve a key rôle in multiple sclerosis, for example because IL-17 levels may correlate with multiple sclerosis lésions, IL-17 can disrupt blood brain barrier endothélial cell tight junctions, and Thl7 cells can migrate into the central nervous System and cause neuronal loss [46,47], Therefore, the compositions of the invention may be particularly effective for preventing or treating multiple sclerosis.
In certain embodiments, treatment with the compositions of the invention results in a réduction in disease incidence or disease severity. fn certain embodiments, the compositions of the invention are for use in reducing disease incidence or disease severity. In certain embodiments, treatment with the compositions of the invention prevents a décliné in motor function or results in improved motor function. In certain embodiments, the compositions of the invention are for use in preventing a décliné in motor function or for use in improving motor function. In certain embodiments, treatment with the compositions of the invention prevents the development of paralysis. In certain embodiments, the compositions of the invention are for use in preventing paralysis in the treatment of multiple sclerosis.
The compositions of the invention may be useful for modulating a patient’s immune system, so in certain embodiments the compositions of the invention are for use in preventing multiple sclerosis in a patient that has been identified as at risk of multiple sclerosis, or that has been diagnosed with early-stage multiple sclerosis or “relapsing-remitting” multiple sclerosis. The compositions of the invention may be useful for preventing the development of sclerosis.
The compositions of the invention may be useful for managing or alleviating multiple sclerosis. The compositions of the invention may be particularly useful for reducing symptoms associated with multiple sclerosis. Treatment or prévention of multiple sclerosis may refer to, for example, an alleviation of the severity of symptoms or a réduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.
Modes of administration
Preferably, the compositions of the invention are to be administered to the gastrointestinal tract in order to enable delivery to and / or partial or total colonisation of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but they may be administered rectally, intranasally, or via buccal or sublingual routes.
In certain embodiments, the compositions of the invention may be administered as a foam, as a spray or a gel.
In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of a theobroma oil (cocoa butter), synthetic hard fat (e.g. suppocire, witepsol), glycero-gelatin, polyethylene glycol, or soap glycerin composition.
In certain embodiments, the composition of the invention is administered to the gastrointestinal tract via a tube, such as a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J tube), percutaneous endoscopie gastrostomy (PEG), or a port, such as a chest wall port that provides access to the stomach, jéjunum and other suitable access ports.
The compositions of the invention may be administered once, or they may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention are to be administered daily.
In certain embodiments of the invention, treatment according to the invention is accompanied by assessment of the patient’s gut microbiota. Treatment may be repeated if delivery of and / or partial or total colonisation with the strain of the invention is not achieved such that efficacy is not observed, or treatment may be ceased if delivery and / or partial or total colonisation is successful and efficacy is observed.
In certain embodiments, the composition of the invention may be administered to a prégnant animal, for example a mammal such as a human in order to prevent an inflammatory or autoimmune disease developing in her child in utero and / or after it is bom.
The compositions of the invention may be administered to a patient that has been diagnosed with a disease or condition mediated by IL-17 or the Thl7 pathway, or that has been identified as being at risk of a disease or condition mediated by IL-17 or the Thl7 pathway. The compositions may also be administered as a prophylactic measure to prevent the development of diseases or conditions mediated by IL-17 or the Thl 7 pathway in a healthy patient.
The compositions of the invention may be administered to a patient that has been identified as having an abnormal gut microbiota. For example, the patient may hâve reduced or absent colonisation by Erysipela toclostridii un.
The compositions of the invention may be administered as a food product, such as a nutritional supplément.
Generally, the compositions of the invention are for the treatment of humans, although they may be used to treat animais including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for enhancing the growth and performance of animais. If administered to animais, oral gavage may be used.
Compositions
Generally, the composition of the invention comprises bacteria. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise granules or gelatin capsules, for example hard gelatin capsules, comprising a bacterial strain of the invention.
Preferably, the composition of the invention comprises lyophilised bacteria. Lyophilisation of bacteria is a well-established procedure and relevant guidance is available in. for example, references [48-50],
Alternatively, the composition of the invention may comprise a live, active bacterial culture.
In some embodiments, the bacterial strain in the composition of the invention has not been inactivated, for example, has not been heat-inactivated. In some embodiments, the bacterial strain in the composition of the invention has not been killed, for example, has not been heat-kiiled. In some embodiments, the bacterial strain in the composition of the invention has not been attenuated, for example, has not been heat-attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention has not been killed, inactivated and/or attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention is live. For example, in some embodiments, the bacterial strain in the composition of the invention is viable. For example, in some embodiments, the bacterial strain in the composition of the invention is capable of partially or totally colonising the intestine. For example, in some embodiments, the bacterial strain in the composition of the invention is viable and capable of partially or totally colonising the intestine.
In some embodiments, the composition comprises a mixture of live bacterial strains and bacterial strains that hâve been killed.
In preferred embodiments, the composition of the invention is encapsulated to enable delivery of the bacterial strain to the intestine. Encapsulation protects the composition from dégradation until delivery at the target location through, for example, rupturing with Chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which may be triggered by changes in pH. Any appropriate encapsulation method may be used. Exemplary encapsulation techniques include entrapment within a porous matrix, attachment or adsorption on solid carrier surfaces, selfaggregation by flocculation or with cross-linkîng agents, and mechanical containment behind a microporous membrane or a microcapsule. Guidance on encapsulation that may be useful for preparing compositions of the invention is available in, for example, references [51] and [52],
The composition may be administered orally and may be in the form of a tablet, capsule or powder. Encapsulated products are preferred because Erysipelatoclostridium ramositm are anaerobes. Other ingrédients (such as vitamin C, for example), may be included as oxygen scavengers and prebiotic substrates to improve the delivery and / or partial or total colonisation and survival in vivo. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey based fermented datry product, or as a pharmaceutical product.
The composition may be formulated as a probiotic.
A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufïïcient to exert a bénéficiai effect upon a patient. A therapeutically effective amount of a bacterial strain may be sufficient to resuit in delivery to and / or partial or total colonisation of the patient’s intestine.
A suitable daily dose of the bacteria, for example for an adult human, may be from about l x !0J to about l x ΙΟ colony forming units (CFU); for example, from about l x 107 to about l x 1OI0 CFU; in another example from about l x 106 to about IxlO10 CFU.
In certain embodiments, the composition contains the bacterial strain in an amount of from about 1 x 106 to about 1 x 1011 CFU/g, respect to the weight of the composition; for example, from about 1 x 108 to about IxlO10 CFU/g. The dose may be, for example, 1 g, 3g, 5g, and 10g.
Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalactooligosaccharides.
In certain embodiments, the probiotic composition of the présent invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, respect to the total weight composition, (e.g. from 5 to 20% by weight). Carbohydrates may be selected from the group consisting of: fructo- oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomaltoligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), betaglucans, arable gum modified and résistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats, and citrus fibers. In one aspect, the prebiotics are the short-chain fructo-oligosaccharides (for sîmplicity shown herein below as FOSs-c.c); said FOSs-c.c. are not digestible carbohydrates, generally obtained by the conversion of the beet sugar and including a saccharose molécule to which three glucose molécules are bonded.
The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients may be found in the reference [53], Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [54], Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnésium stéarate, mannitol, sorbitol and the like. Examples of suitable diluents include éthanol, glycerol and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s). Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, freeflow lactose, beta-lactose, com sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stéarate, magnésium stéarate, sodium benzoate, sodium acetate, sodium chloride and the like. Preservatives, stabilizers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.
The compositions of the invention may be formulated as a food product. For example, a food product may provide nutritional benefit in addition to the therapeutic effect of the invention, such as in a nutritional supplément. Sîmilarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive to consume by being more similar to a common food item, rather than to a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The tenu milk-based product means any liquid or semi-solid milk- or whey- based product having a varying fat content. The milk-based product can be, e.g., cow's milk, goat’s milk, sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk and whey without any processing, or a processed product, such as yoghurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk beverages, such as whey beverages, fermented milks, condensed milks, infant or baby milks; flavoured milks, ice cream; milk-containing food such as sweets.
In some embodiments, the compositions of the invention comprise one or more bacterial strains of the genus Erysipelatoclostridium and do not contain bacteria from any other genus, or which comprise only de minimis or bîologically irrelevant amounts of bacteria from another genus. Thus, in some embodiments, the invention provides a composition comprising one or more bacterial strains of the genus Erysipelatoclostridium, which does not contain bacteria from any other genus or which comprises only de minimis or bîologically irrelevant amounts of bacteria from another genus, for use in therapy.
In certain embodiments, the compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strains or species. Such compositions may comprise only de minimis or bîologically irrelevant amounts of other bacterial strains or species. Such compositions may be a culture that is substantially free from other species of organism. Thus, in some embodiments, the invention provides a composition comprising a single bacterial strain or species of the genus Erysipelatoclostridium, which does not contain bacteria from any other genus or which comprises only de minimis or bîologically irrelevant amounts of bacteria from another genus for use in therapy.
In some embodiments, the compositions of the invention comprise more than one bacterial strain or species. For example, in some embodiments, the compositions of the invention comprise more than one strain from within the same species (e.g. more than l, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise less than 50 strains from within the same species (e.g. less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 250, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25, or 31-50 strains from within the same species and. optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise more than one species from within the same genus (e.g. more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions of the invention comprise less than 50 species from within the same genus (e.g. less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5, 4 or 3 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions ofthe invention comprise 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15,2-10, 2-5,6-30, 6-15, 16-25, or 3150 species from within the same genus and, optionally, do not contain bacteria from any other genus. The invention comprises any combination of the foregoing.
In some embodiments, the composition comprises a microbial consortium. For example, in some embodiments, the composition comprises the Erysipelatoclostridium bacterial strain as part of a microbial consortium. For example, in some embodiments, the Erysipelatoclostridium bacterial strain is présent in combination with one or more (e.g. at least 2, 3, 4, 5, 10, 15 or 20) other bacterial strains from other généra with which it can live symbiotically in vivo in the intestine. For example, in some embodiments, the composition comprises a bacterial strain of Erysipelatoclostridium ramosum in combination with a bacterial strain from a different genus. In some embodiments, the microbial consortium comprises two or more bacterial strains obtained from a faeces sample of a single organism, e.g. a human. In some embodiments, the microbial consortium is not found together în nature. For example, in some embodiments, the microbial consortium comprises bacterial strains obtained from faeces samples of at least two different organisms. In some embodiments, the two different organisms are from the same species, e.g. two different humans. In some embodiments, the two different organisms are an infant human and an adult human. In some embodiments, the two different organisms are a human and a non-human mammal.
In some embodiments, the composition of the invention additionally comprises a bacterial strain that has the same safety and therapeutic efficacy characteristics as strain MRX027 deposited as NCIMB 42688, but which is not MRX027 deposited as NCIMB 42688, or which is not a Erysipelatoclostridium ramosum or which is not an Erysipelatoclostridium.
In some embodiments in which the composition of the invention comprises more than one bacterial strain. species or genus, the individual bacterial strains, species or généra may be for separate, simultaneous or sequential administration. For example, the composition may comprise ail of the more than one bacterial strain, species or généra, or the bacterial strains, species or généra may be stored separately and be administered separately, simultaneously or sequentially. In some embodiments, the more than one bacterial strains, species or généra are stored separately but are mixed together prior to use.
In some embodiments, the bacterial strain for use in the invention is obtained from human adult faeces. In some embodiments in which the composition of the invention comprises more than one bacterial strain, ail of the bacterial strains are obtained from human adult faeces or if other bacterial strains are present they are present only in de minimis amounts. The bacteria may hâve been cultured subséquent to being obtained from the human adult faeces and being used in a composition of the invention.
As mentioned above, in some embodiments, the one or more Erysipelatoclostridiiim bacterial strains is/are the only therapeutically active agent(s) in a composition of the invention. In some embodiments, the bacterial strain(s) in the composition is/are the only therapeutically active agent(s) in a composition of the invention.
The compositions for use in accordance with the invention may or may not require marketing approval.
In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised. In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is spray dried. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is live. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is viable. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is capable of partially or totally colonising the intestine. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it îs viable and capable of partially or totally colonising the intestine.
In some cases, the lyophilised or spray dried bacterial strain is reconstituted prior to administration. In some cases, the reconstitution is by use of a diluent described herein.
The compositions of the invention can comprise pharmaceutically acceptable excipients, diluents or carriers.
In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain as used in the invention; and a pharmaceutically acceptable excipient, carrier or diluent;
wherein the bacterial strain is in an amount sufficient to treat a disorder when administered to a subject in need thereof; and wherein the disorder is selected from the group consisting of uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvénile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease or ulcerative colîtîs; celîac disease; asthma, such as allergie asthma or neutrophilie asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopie dermatitis; emphysema; periodontitis; allergie rhinitis; and allograft rejection.
In certain embodiments, the invention provides pharmaceutical composition comprising: a bacterial strain as used in the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain îs in an amount sufficient to treat or prevent a disease or condition mediated by IL-17 or the Thl7 pathway. In preferred embodiments, said disease or condition is selected from the group consisting of uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvénile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; celiac disease; asthma, such as allergie asthma or neutrophilie asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopie dermatitis; emphysema; periodontitis; allergie rhinitis; and allograft rejection.
In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about l * 103 to about l x 1011 colony foiming units per gram with respect to a weight of the composition.
In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of l g, 3 g. 5 g or 10 g.
In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subeutaneous, nasal, buccal, and sublingual.
In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methyl cellulose, magnésium stéarate, mannitol and sorbitol.
In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of éthanol, glycerol and water.
3l
In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, freeflow lactose, beta-lactose, corn sweetener, acacia, tragacanth, sodium alginate, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stéarate, magnésium stéarate, sodium benzoate, sodium acetate and sodium chloride.
In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant and a stabilizer.
In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid and esters of phydroxybenzoic acid.
In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is piaced în an atmosphère having 50% relative humidity, at least 80% of the bacterial strain as measured in colony forming units, remains after a period of at least about: l month, 3 months, 6 months, l year, 1.5 years, 2 years, 2.5 years or 3 years.
In some embodiments, the composition of the invention is provided in a sealed container comprising a composition as described herein. In some embodiments, the sealed container is a sachet or bottle. In some embodiments, the composition of the invention is provided in a syringe comprising a composition as described herein.
The composition of the present invention may, in some embodiments, be provided as a pharmaceutical formulation. For example, the composition may be provided as a tablet or capsule. In some embodiments, the capsule is a gélatine capsule (gel-cap”).
In some embodiments, the compositions of the invention are administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the inouth.
Pharmaceutical formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed Systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), émulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
In some embodiments the pharmaceutical formulation is an enteric formulation, Le. a gastro-résistant formulation (for example, résistant to gastric pH) that is suitable for delivery of the composition of the invention to the intestine by oral administration. Enteric formulations may be particularly useful when the bacteria or another component of the composition is acid-sensitive, e.g. prone to dégradation under gastric conditions.
In some embodiments, the enteric formulation comprises an enteric coating. In some embodiments, the formulation is an enteric-coated dosage form. For example, the formulation may be an entericcoated tablet or an enteric-coated capsule, or the like. The enteric coating may be a conventional enteric coating, for example, a conventional coating for a tablet, capsule, or the like for oral delivery. The formulation may comprise a film coating, for example, a thîn film layer of an enteric polymer, e.g. an acid-insoluble polymer.
In some embodiments, the enteric formulation is intrinsically enteric, for example, gastro-résistant without the need for an enteric coating. Thus, in some embodiments, the formulation is an enteric formulation that does not comprise an enteric coating. In some embodiments, the formulation is a capsule made from a thermogelling material. In some embodiments, the thermogelling material is a cellulosic material, such as methylcellulose, hydroxymethylcellulose or hydroxypropylmethylcellulose (HPMC). In some embodiments, the capsule comprises a shell that does not contain any film formîng polymer. In some embodiments, the capsule comprises a shell and the shell comprises hydroxypropylmethylcellulose and does not comprise any film formîng polymer (e.g. see [55 ]). In some embodiments, the formulation is an intrinsically enteric capsule (for example, Vcaps® from Capsugel).
In some embodiments, the formulation is a soft capsule. Soft capsules are capsules which may, owing to additions of softeners, such as, for example, glycerol, sorbitol, maltitol and polyethylene glycols, present in the capsule shell, hâve a certain elasticity and softness. Soft capsules can be produced, for example, on the basis of gélatine or starch. Gelatine-based soft capsules are commercially available from various suppliers. Depending on the method of administration, such as, for example, orally or rectally, soft capsules can hâve various shapes, they can be, for example, round, oval, oblong or torpedo-shaped. Soft capsules can be produced by conventional processes, such as, for example, by the Scherer process, the Accogel process or the droplet or blowing process.
Culturing methods
The bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed in, for example, references [56-58],
The solid or liquid medium used for culture may be YCFA agar or YCFA medium. YCFA medium may include (per 100ml, approximate values): Casitone (l.O g), yeast extract (0.25 g), NaHCOj (0.4 g), cysteine (0.1 g), K2HPO4 (0.045 g), KH2PO4 (0.045 g), NaCl (0.09 g), (NH4)2SO4 (0.09 g),
MgSO4 · 7H;O (0.009 g), CaCb (0.009 g), resazurin (O.l mg), hemin (l mg), biotin (l pg). cobalamin (l pg),/?-aminobenzoic acid (3 pg), folie acid (5 pg), and pyridoxamine (15 pg).
Bacterial strains far use in vaccine compositions
The inventors hâve identified that the bacterial strains of the invention are useful for treating or preventing diseases or conditions mediated by IL-17 or the Thl7 pathway. This is likely to be a resuit of the effect that the bacterial strains of the invention hâve on the host immune system. Therefore, the compositions of the invention may also be useful for preventing diseases or conditions mediated by IL-17 or the Thl7 pathway, when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention are viable. In certain such embodiments, the bacterial strains of the invention are capable of partially or totally colonising the intestine. In certain such embodiments, the bacterial strains of the invention are viable and capable of partially or totally colonising the intestine. In other certain such embodiments, the bacterial strains of the invention may be killed, inactivated or attenuated. In certain such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration via injection, such as via subeutaneous injection.
General
The practice ofthe présent invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular bîology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., references [59] and [60-66], etc.
The term “comprising” encompasses “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X + Y.
The term “about” in relation to a numerical value x is optional and means, for example, x+10%.
The word “substantially” does not exclude “completely” e.g. a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the définition of the invention,
References to a percentage sequence identity between two nucléotide sequences means that, when aligned, that percentage of nucléotides are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. [67]. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The SmithWaterman homology search algorithm is disclosed in ref. [68].
Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the méthod, or may comprise additional intervening steps. Also, steps may be combined, omitted or performed in an alternative order, if appropriate.
Various embodiments of the invention are described herein. It will be appreciated that the features specified in each embodiment may be combined with other specified features, to provide further embodiments. In particular, embodiments highlighted herein as being suitable, typical or preferred may be combined with each other (except when they are mutually exclusive).
MODES FOR CARRYING OUT THE INVENTION
Example 1 — Efficacy of bacterial inocula in a mouse model of uveitis
Summarv
This study used a mouse model of interphotoreceptor retinoid-binding protein (IRBP)-induced uveitis to test the effects of bacterial administration on uveitis. Uveitis is a sight-threatening condition resulting from intraocular inflammation and retinal tissue destruction. This disease can be studied in rodents in a model of experimental autoimmune uveoretinitis (EAU) [69]. EAU is an organ-specific disorder where Thl/Thl7 cells are directed toward retinal antigens and produce cytokines that activate résident and infiltrating mononuclear cells leading to tissue destruction. EAU can be induced in mice by challenge with retinal antigens including interphotoreceptor retinoid binding protein peptide (IRBPp). Disease onset normally occurs from day 8-9 and peaks after days 14-15. Signs of clinîcal disease can be monitored using topical endoscopie fundal imaging (TEFI).
Strain
MRX027: Etysipelatoclostridium ramosum.
The strain used in this example has been deposited as NCIMB 42688.
Biotherapeutic was provided in glycerol stock. Microbiological growth media (YCFA) was used for the culture ofthe agent.
Mice
The mice were strain C57BL/6 and were over 6 weeks old at the beginning of the study. 72 mice were used (+ 36 Satellite animais). Unhealthy animais were excluded from the study. Animais were housed in spécifie pathogen free (spf) conditions, in a thermostatically monitored holding room (22 ± 4°C). Animais were allowed to acclimatise under standard animal house conditions for a minimum of one week prior to use. The health status of the animais was monitored throughout this period and the suitabîlity of each animal for experimental use was assessed prior to study start. Mice were housed in groups of up to 10 animais per cage for the duration of the study. Irradiated pellet diet (Lab diet, EU
Rodent diet 22%, 5LF5) and water were available ad libitum throughout the acclimatisation and study periods. It is unlikely that any constituent of the diet or water interfered with the study.
Experimental Outline
Adult female C57BL/6 mice were randomly allocated to experimental groups and allowed to acclimatise for one week. Treatments were administered according to the schedule below. On Day 0, animais were administered with an émulsion containing 200 pg of interphotoreceptor retinoid binding protein peptide l-20 (IRBP p I -20) in complété Freund’s adjuvant (CFA) supplemented with
2.5 mg/ml Mycobacterium Tuberculosis H37 Ra by subcutaneous injection. Also on Day 0, animais were administered with l .5 pg Bordetella Pertussis toxin by intra-peritoneal injection. From Day 14, animais are weighed three times per week. From Day -l untîl the end of the experiment on Day 42, animais are monitored twice per week for clinical signs of uveitis using topical endoscopie fondai imaging (TEFI).
Administration schedule
Ali Groups are n=I2
Vehicle for oral administration is YCFA medium.
Administration volume for twice daily oral administration is 5 ml/kg.
Group | Treatment | Dose | Route | Frequency | Disease Induction |
1 | i'ehicle | 5 ml/kg | PO | BID Day -14-End | Day 0: IRBP/CFA, SC Day 0: PTx, IP |
2 | MRXQ27 | 5 ml/kg |
PO: oral administration, BID: twice daily, SC: subcutaneous injection. IP: intra-peritoneal injection, IRBP: interphotoreceptor binding protein, CFA: complété Freund’s adjuvant, PTx: Pertussis toxin
A positive control group was also tested using treatment with the drug cyclosporin A.
Readouts
Bodyweights. From Day -14, animais are weighed three times a week. Animais with a bodyweight loss equal to or greater than 15% of their initial (Day 0) bodyweight on two consecutive occasions are culled.
Non-specific clinical observations. From Day -I4 until the end of the experiment, animais are checked daily for non-specific clinical signs to include abnormal posture (hunched), abnormal coat condition (piloerection) and abnormal activity levels (reduced or increased activity).
Clinical Scores: Retinal imaging by topical endoscopie fundal imaging (TEFI). From Day -l until the end of the experiment, animais are scored twice per week for clinical signs of uveitis.
Retinal images are captured using TEFI in non-anaesthetised but restrained animais following pupil dilatation using Tropicamide l% then Phenylephrine hydrochloride 2.5%. Retinal images are scores using the following system. The maximum cumulative score is 20.
Score | Optic dise Inflammation | Retinal vessels | Retinal tissue Infiltration | Structural damage |
l | Minimal | l -4 mild euffings | l-4 small lésions or l linear lésion | Retinal lésions or atrophy involving % to % of retinal area |
2 | Mild | >4 mild euffings or l -3 moderate euffings | 5-10 small lésions or 2-3 linear lésions | Panretinal atrophy with multiple small lésions (scars) or <3 linear lésions (scars) |
3 | Moderate | >3 moderate euffings | >10 small lésions or >3 linear lésions | Panretinal atrophy with >3 linear lésions or confluent lésions (scars) |
4 | Severe | >l severe euffings | Linear lésion confluent | Retinal detachment with folding |
5 | Not visible (white-out or severe detachment) |
Results
The results of the study are shown in Figures l and 2.
Clinical Scores: Retinal imaging by topical endoscopie fundal imaging (TEFI). TEFI scores data measured in the Control group from Day 0 until Day 28 were analysed by Kruskal-Wallis test for non-parametric data followed by Dunn’s post-test for multiple comparisons between experimental days.
1RBP administration induced a significant increase in the TEFI scores measured from Day 14 (p < 0.01 ) and on Day 28 (p < 0.0001 ) when compared to Day 0 in the Control group (Figure l ).
TEFI scores measured in the experimental groups on Day 28 were analysed using a one-way ANOVA. As expected, a significant decrease in the scores was observed in the positive control cyclosporine A group. There was also a statistically significant decrease in the scores for the 15 MRX027-treated group (p<0.05), relative to the négative control (Figure 73).
Conclusions. Clinical scores determined by TEFI increased from Day 14, as expected in this model of IRBP-induced uveitis. By Day 28, a striking and statistically significant réduction in disease incidence and disease severity was observed in the MRX027-treated group, which was comparable to that seen for the positive control group. In particular, these data indicate that treatment with the strain MRX027 reduced retinal damage, optic dise inflammation and/or retinal tissue infiltration by inflammatory cells (see TEFI retinal image scoring system above). These data indicate the strain MRX027 may be useful for treating or preventing uveitis.
Example 2 - Stability' testing
A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25°C or 4°C and the container is placed in an atmosphère having 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After l month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, at least 50%, 60%, 70%, 80% or 90% ofthe bacterial strain shall remain as measured in colony forming units determined by standard protocols.
Sequences
SEQ ID NO:1 [Erysipelatoclostridium (Clostridium) ramosum 16S rRNA gene, strain DSM 1402 X73440) nnnnnnngag agtttgatcc tggctcagga tgaacgctgg cggcgtgcct aatacatgca agtegaaege gageaettgt gctcgagtgg cgaacgggtg agtaatacat aagtaacctg
121 ccctagacag ggggataact attggaaacg gatagctaag accgcatagg tacggacact
181 gcatggùgac cgtattaaaa gtgcctcaaa gcactggtag aggatggact tatggcgcat
241 tagctggttg gcggggtaac ggcccaccaa ggcgacgatg cgtagccgac ctgagagggt
301 gaccggccac actgggactg agacacggcc cagactccta cgggaggcag cagtagggaa
361 ttttcggcaa tgggggaaac cctgaccgag caacgccgcg tgaaggaaga aggttttcgg
421 attgtaaact tctgttataa agaagaacgg cggctacagg aaatggtagc cgagtgacgg
481 tactttattt tagaaagcca cggctaacta cgtgccagca gccgcggtaa tacgtaggtg
541 gcaagcgtCa cccggaatta ttgggcgtaa agagggagea ggcggcagca agggtctgtg
601 gtgaaagcct gaagcttaac ttcagtaagc catagaaacc aggeagetag agtgcaggag
661 aggatcgtgg aattccatgt gtagcggtga aatgcgtaga tatatggagg aacaccagtg
721 gcgaaggcga cgatctggcc tgcaactgac gctcagtccc gaaagcgtgg ggagcaaata
781 ggattagata ccctagtagt ccacgccgta aacgatzgagt actaagtgtt ggatgtcaaa
841 gttcagtgct gcagttaacg caataagtac tccgcctgag cagtacgttc gcaagaaCga
901 aactcaaagg aattgacggg ggccgcacaa gcggtggagc atgtggttta actegaagea
961 acgcgaagaa ccttaccagg tcttgacata ctcataaagg ctccagagat ggagagatag
1021 ctatatgaga tacaggtggt gcatggttgt cgtcagctcg tgtcgtgaga tgttgggtta
1081 agtcccgcaa cgagcgcaac ccttatcgtt agttaccatc attaagttgg ggactctagc
1141 gagactgcca gtgacaagct ggaggaaggc ggggatgacg tcaaatcatc atgcccctta
1201 tgacctgggc tacacacgtg ctacaatgga tggtgcagag ggaagcgaac cgcgaggtga
1261 agcaaaaccc ataaaaacca ttctcagttc ggattgtagt ctgcaactcg actacatgaa
1321 gttggaatcg ctagtaatcg cgaatcagca tgtcgcggtg aatacgttct cgggccttgt
1381 acacaccgcc cgtcacacca cgagagttga taacacccga agccggtggc ctaaccgcaa
1441 ggaaggagct gtctaaggtg ggattgatga ttggggtgaa gtcgtaacaa ggtatcccta
1501 cgggaacgtg cggctggatc acctcc
SEQ ID NO:2 (Erysipelatoclostridium ramosum strain JCM 1298 16S ribosomal RNA gene, partial sequence - NR_113243.1)
1 | agagtttgat | cctggctcag | gatgaacgct | ggcggcgtgc | ctaatacatg | caagtcgaac |
61 | gcgagcactt | gtgctcgagt | ggcgaacggg | tgagtaatac | ataagtaacc | tgccctagac |
121 | agggggataa | ctat tggaaa | cgatagctaa | gaccgcatag | gtacggacac | tgcatggtga |
181 | ccgtattaaa | agtgcctcaa | agcactggta | gaggatggac | ttatggcgca | ttagctggtt |
241 | ggcggggtaa | cggcccacca | aggcgacgat | gcgtagccga | cctgagaggg | tgaccggcca |
301 | cactgggact | gagacacggc | ccagactcct | acgggaggca | gcagtaggga | attttcggca |
361 | atgggggaaa | ccctgaccga | gcaacgccgc | gtgaaggaag | aaggttttcg | gattgtaaac |
421 | ttctgttata | aaggaagaac | ggcggctaca | ggaaatggta | gccgagtgac | ggtactttat |
481 | tagaaagcca | cggctaacta | cgtgccagca | gccgcggtaa | tacgtaggtg | gcaagcgtta |
541 | tccggaatta | ttgggcgtaa | agagggagca | ggcggcagca | agggtctgtg | gtgaaagcct |
601 | gaagcttaac | ttcagtaagc | catagaaacc | aggcagctag | agtgcaggag | aggatcgtgg |
661 | aat tccatgt | gtagcggtga | aatgcgtaga | tatatggagg | aacaccagtg | gcgaaggcga |
721 | cgatctggcc | tgcaactgac | gctcagtccc | gaaagcgtgg | ggagcaaata | ggattagata |
781 | ccctagtagt | ccacgccgta | aacgatgagt | actaagtgtt | ggatgtcaaa | gttcagtgct |
841 | gcagttaacg | caataagtac | tccgcctgag | tagtacgt te | gcaagaatga | aactcaaagg |
901 | aat tgacggg | ggcccgcaca | agcggtggag | catgtggttt | aattcgaagc | aacgcgaaga |
961 | accttaccag | gtcttgacat | actcataaag | gctccagaga | tggagagata | gctatatgag |
1021 | atacaggtgg | tgcatggttg | tcgtcagctc | gtgtcgtgag | atgttgggtt | aagtcccgca |
1081 | acgagcgcaa | cccttatcgt | tagttaccat | cat taagt tg | gggactctag | cgagactgcc |
1141 | agtgacaagc | tggaggaagg | cggggatgac | gtcaaatcat | catgcccct t | atgacctggg |
1201 | ctacacacgt | gctacaatgg | atggtgcaga | gggaagcgaa | gccgcgaggt | gaagcaaaac |
1261 | ccataaaacc | attctcagtt | cggattgtag | tctgcaactc | gactacatga | agttggaatc |
1321 | gctagtaatc | gcgaatcagc | atgtcgcggr | gaatacgttc | tcgggccttg | tacacaccgc |
1381 | ccgtcacacc | acgagagttg | ataacacccg | aagccggtgg | cctaaccgca | aggaaggage |
1441 | tgtctaaggt | gggattgatg | attggggtga | agtcgtaaca | aggtaacc |
SEQ ID NO:3 (consensus 16S rRNA sequence for Erysipelatoclostridium ramosum strain MRX027)
TGCGGTTAGGCCACCGGCTTCGGGTGTTATCAACTCTCGTGGTGTGACGGGCGGTGTGTACAAGGCCCGAGAACGTA
TTCACCGCGACATGCTGATTCGCGATTACTAGCGATTCCAACTTCATGTAGTCGAGTTGCAGACTACAATCCGAACT
GAGAATGGTTTTATGGGTTTTGCTTCACCTCGCGGCTTCGCTTCCCTCTGCACCATCCATTGTAGCACGTGTGTAGC
CCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCGCCTTCCTCCAGCTTGTCACTGGCAGTCTCGCTAGAGTC
CCCAACTTAATGATGGTAACTAACGATAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCT
GACGACAACCATGCACCACCTGTATCTCATATAGCTATCTCTCCATCTCTGGAGCCTTTATGAGTATGTCAAGACCT
GGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGT
TTCATTCTTGCGAACGTACTACTCAGGCGGAGTACTTATTGCGTTAACTGCAGCACTGAACTTTGACATCCAACACT
TAGTACTCATCGTTTACGGCGTGGACTACTAGGGTATCTAATCCTATTTGCTCCCCACGCTTTCGGGACTGAGCGTC
AGTTGCAGGCCAGATCGTCGCCTTCGCCACTGGTGTTCCTCCATATATCTACGCATTTCACCGCTACACATGGAATT
CCACGATCCTCTCCTGCACTCTAGCTGCCTGGTTTCTATGGCTTACTGAAGTTAAGCTTCAGGCTTTCACCACAGAC
CCTTGCTGCCGCCTGCTCCCTCTTTACGCCCAATAATTCCGGATAACGCTTGCCACCTACGTATTACCGCGGCTGCT
GGCACGTAGTTAGCCGTGGCTTTCTAATAAAGTACCGTCACTCGGCTACCATTTCCTGTAGCCGCCGTTCTTCCTTT
ATAACAGAAGTTTACAATCCGAAAACCTTCTTCCTTCACGCGGCGTTGCTCGGTCAGGGTTTCCCCCATTGCCGAAA
ATTCCCTACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGGTCACCCTCTCAGGTCGGC
TACGCATCGTCGCCTTGGTGGGCCGTTACCCCGCCAACCAGCTAATGCGCCATAAGTCCATCCTCTACCAGTGCTTT GAGGCACTTTTAATACGGTCACCATGCAGTGTCCGTACCTATGCGGTCTTAGCTATCGTTTCCAATAGTTATCCCCC TGTCTAGGGCAGGTTACTTATGTATTACTCACCCGTTCGCCACTCGAGCACAAGTGCTCGC
SEQ ID NO:4 (genome sequence of Erysipelatoclostridium ramosum strain DSM 140) - see electronic sequence listing.
REFERENCES
[ 1 ] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.
[2] EckburgeZfl/. (2005) Science. 10;308(5728): 1635-8.
[3] Macpherson et al. (2001) Microbes Infect. 3(12):1021-35
[4] Macpherson et al. (2002) Cell Mol Life Sci. 59( 12):2088-96.
[5] Mazmanian et al. (2005) Cell 15;122(1): 107-18.
[6] Frank et al. (2007) PNAS 104(34):13780-5.
[7] Scanlan et al. (2006) J Clin Microbiol. 44( 11 ):3980-8.
[8] Kang et al. (2010) Inflamm Bowel Dis. 16( 12):2034-42.
[9] Machiels étal. (2013) Gut. 63(8):1275-83.
[10] WO 2013/050792
[11] WO 03/046580
[12] WO 2013/008039
[13] WO 2014/167338
[14] Goldin and Gorbach (2008) Clin Infect Dis. 46 Suppl 2:S96-100.
[15] Azad étal. (20H) BMJ. 347:f6471.
[16] WO2015/095241
[17] WO2015/156419
[18] Yutinand Galperin (2013) Environ Microbiol. 15(10): 2631-2641.
[19] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563.
[20] Srûtkovâ étal. (2011) J. Microbiol. Methods, 87(1):10-6.
[21 ] Ye et al. (2015) PLoS One. 10( I ):e0117704.
[22] Fabro et al. (2015) Immunobiology. 220(1):124-35.
[23] Yin et al. (2014) Immunogenetics. 66(3):215-8.
[24] Cheluvappa et al. (2014) Clin Exp Immunol. 175(2):316-22.
[25] Schieck et al. (2014) J Allergy Clin Immunol. 133(3):888-91.
[26] Balatoe/n/. (2014) J Eur Acad Dermatol Venereol. 28(8):1016-24.
[27] Monteleone et al. (2011) BMC Medicine. 2011,9:122.
[28] Zhang (2015) Inflammation. Aug 23.
[29] Sun et al. (2015) Cytokine. 74(1):76-80.
[30] Mucientes et al. (2015) BrJOphthalmol. 99(4):566-70.
[31] Jawad et al. (2013) Ocul Immunol Inflamm. 21(6):434-9.
[32] Maya et al. (2014) J. Ophthalmology. 310329
[33] Chi et al. (2007) J. Allergy and Clinicai Immunology. 119(5): 1218 1224.
[34] Chi et al. (2008) Investigative Ophthalmology’ &Visual Science. 49(7): 3058-3064.
[35] Luger and Caspi (2008) Semin. Immunopathol. 30(2): 134-143.
[36] Numasaki et al. (2003) Blood. 101:2620-2627.
[37] Zhang et al. (2008) Biochem. Biophys. Res. Commun. 374: 533-537.
[38] Karin (2006) Nature. 441: 431-436.
[39] Faghih et al. (2013). Iranian Journal of Immunology. 10(4):193-204.
[40] Numasaki et al. (2005) J. Immunol. 175: 6177-6189
[41] Hammerich and Tacke (2014) Clin Exp Gastroenterol. 7:297-306.
[42] Fahy (2009) Proc Am Thorac Soc 6.256-259
[43] Miossec and Kolls (2012) Nat Rev Drug Discov. 11(10):763-76.
[44] Yang et al. (2014) Trends Pharmacol Set. 35(10):493-500.
[45] Koenders et al. (2006) J. Immunol. 176:6262-6269.
[46] Amedei et al. (2012) Int J Mol Sci. 13(10):13438-60.
[47] Shabgah et al. (2014) Postepy. Dermatol. Alergol. 31(4):256-61.
[48] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol., 54, 9-24.
[49] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.
[50] Leslie et al. (1995) Appl. Environ. Microbiol. 61, 3592-3597.
[51] Mitropoulou et al. (2013) JNutr Metab. (2013) 716861.
[52] Kailasapathy et al. (2002) Curr Issues Intest Microbiol. 3(2):39-48.
[53] Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and P J Weller
[54] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985)
[55] US 2016/0067188
[56] Handbook of Microbiological Media, Fourth Edition /2010) Ronald Atlas, CRC Press.
[57] Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academie Press
[58] Strobel (2009) Methods Mol Biol. 581:247-61.
[59] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th édition, ISBN: 0683306472.
[60] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., 1998, Academie Press).
[61] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academie Press, Inc.)
[62] Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, 1986, Blackwell Scientific Publications)
[63] Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd édition (Cold Spring Harbor Laboratory Press).
[64] Handbook of Surface and Colloïdal Chemistry (Birdi, K.S. ed., CRC Press, 1997)
[65] Ausubel et al. (eds) (2002) Short protocols in molecular biology, 5th édition (Current Protocols).
[66] PCR (Introduction to Biotechniques Sériés), 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)
[67] Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplément 30
[68] Smith & Waterman (1981) Adv. Appl. Math. 2: 482-489.
[69] Caspi (2003) Curr Protoc Immunol. Chapter 15:Unit 15.6.
Claims (24)
1. A composition comprising a bacterial strain of the species Erysipelatoclostridium ramosum, for use in a method of treating or preventing an inflammatory or autoimmune disease.
2. The composition for use according to claim l, wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of uveitis; multiple sclerosis; arthritis, including rheumatoid arthritis, osteoarthrîtîs, psoriatic arthritis, or juvénile îdiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, including Crohn’s disease or ulcerative colitis; celiac disease; asthma, including allergie asthma or neutrophilie asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopie dermatitis; emphysema; periodontitis; allergie rhinitis; and allograft rejection.
3. The composition of claim 2, wherein the composition is for use in a method of treating or preventing uveitis.
4. The composition of claim 3, wherein the composition is for use in a method of reducing or preventing retinal damage in uveitis.
5. The composition of claim 2, wherein the composition is for use in in a method of treating or preventing asthma, such as neutrophilie asthma or allergie asthma
6. The composition of claim 5, wherein the composition is for use in a method of reducing neutrophilia or eosinophilia in the treatment of asthma.
7. The composition of claim 2, wherein the composition is for use in in a method of treating or preventing rheumatoid arthritis.
8. The composition of claim 7, wherein the composition is for use in a method of reducing joint swelling in rheumatoid arthritis.
9. The composition of claim 2, wherein the composition is for use in in a method of treating or preventing multiple sclerosis.
10. The composition of claim 9, wherein the composition is for use in a method of reducing disease incidence or disease severity.
11. The composition of any preceding claim, wherein the composition is for use in a method of reducing IL-17 production or reducing Thl7 cell différentiation in the treatment or prévention of an inflammatory or autoimmune disease.
12. The composition of any preceding claim, wherein the composition is for use in a patient with elevated IL-17 levels or Th17 cells.
13. The composition of any of daims l -12, wherein the bacterial strain has a I6s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: l, 2 or 3.
14. The composition of claim 13, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:3, or wherein the bacterial strain has the I6s rRNA sequence represented by SEQ ID NO:3.
15. The composition of any preceding claim, wherein the bacterial strain is lyophilised.
16. The composition of any preceding claim, wherein the bacterial strain is viable and capable of partially or totally colonising the intestine.
17. The composition of any preceding claim, wherein the composition comprises a single strain of the species Erysipelatoclostridium ramosum and does not contain any other bacterial strains or species or comprises only de minimis or biologically irrelevant amounts of other bacterial strains or species.
18. A food product or vaccine composition comprising the composition of any preceding claim, for the use of any preceding claim.
19. A cell of Erysipelatoclostridium ramosum strain MRX027 deposited as NCIMB 42688, or a dérivative thereof.
20. A composition comprising the cell of claim 19.
21. The composition of claim 20, comprising a pharmaceutically acceptable carrier or excipient.
22. A biologically pure culture of Erysipelatoclostridium ramosum strain MRX027 deposited as NCIMB 42688, or a dérivative thereof.
23. A cell of the Erysipelatoclostridium ramosum strain MRX027 deposited as NCIMB 42688, or a dérivative thereof, for use in therapy.
24. The cell of claim 23, wherein the cell is for use in a method defined in any of daims 1-12.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1520631.1 | 2015-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18797A true OA18797A (en) | 2019-06-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10471108B2 (en) | Compositions comprising bacterial strains | |
US20210069258A1 (en) | Compositions comprising bacterial strains | |
AU2018226438B2 (en) | Compositions comprising bacterial strains | |
OA18797A (en) | Compositions comprising bacterial strains. | |
OA18795A (en) | Compositions comprising bacterial strains. | |
OA18792A (en) | Compositions comprising bacterial strains. |